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Resumo 
O incompleto perfil de segurança dos novos medicamentos e o insuficiente 
conhecimento da relação benefício-risco no momento uma autorização de introdução 
no mercado (AIM) é concedida são premisas estabelecidas em farmacovigilânica. Na 
verdade, elas mesmas justificam a contínua monitorização do perfil de segurança dos 
medicamentos com AIM aprovada e identificação de riscos associados à sua utilização 
– actividades essenciais à manutenção da própria AIM.  
Ora, a deteção e avaliação de reacções adversas aos medicamentos, seguida do 
estabelecimento de medidas de prevenção e minimização de risco, não só fazem parte 
da missão da farmacovigilância, como também integram os objectivos e 
responsabilidades das agências reguladoras e da indústria farmacêutica.  
Algumas publicações científicas procuraram, ao longo dos anos, versar sobre estas 
mesmas medidas de prevenção e minimização de risco, mediante o estudo do conjunto 
de acções regulamentares face a questões de segurança. Na sua maioria, a análise foi 
efectuada em contextos singulares, como o caso de produtos biológicos, medicamentos 
órfãos, medicamentos com AIM concedida em circunstâncias excecionais, ou 
considerando as acções regulamentares no contexto de um determinado país ou 
pequeno grupo de países, como é o caso de exemplos publicados no Reino Unido, 
Espanha, Estados Unidos da América e Holanda. 
Os resultados obtidos sugerem que tais acções regulamentares foram desencadeadas 
pelas autoridades reguladoras em cerca de 9 a 25% dos medicamentos com AIM 
aprovada em análise. Dois outros estudos denotam que, entre 1975 e 1999, pelo menos 
uma acção regulamentar foi tomada em função de problemas de segurança para 10% 
dos medicamentos com AIM aprovada nos Estados Unidos da América. Mais 
recentemente, um conjunto de productos biológicos foi associado a uma probabilidade 
de 14% de necessitar de uma primeira acção regulamentar derivada de questões de 
segurança nos primeiros 3 anos após a aprovação da AIM. Sendo que, para a mesma 
classe de medicamentos, os produtos biológicos com a primeira aprovação de AIM 
possuiam um risco acrescido de requerer tais acções de segurança. 
No entanto, e apesar das várias agências reguladoras dos medicamentos e productos 
de saúde possuírem, objectivos e responsabilidades semelhantes no que tangue à 
necessidade de garantir a qualidade, eficácia e segurança dos medicamentos nos 
mercados em que actuam, nem sempre partilham da mesma interpretação e tomada de 
decisão face a um determinado conjunto de informações de segurança e eficácia para 
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um mesmo medicamento. As diferenças nos enquadramentos regulamentares, nas 
estruturas organizacionais e no modo de funcionamento das agências dos Estados 
Unidos da América (FDA) e da União Europeia (EMA) encontram-se descritas em 
detalhe na literatura publicada, tendo sido extensamente analizadas e comparadas. 
Ao longo das últimas decadas, estas desemelhanças têm conduzindo a avaliações e 
recommendações divergentes. No âmbito da aprovação de medicamentos e produtos 
de saúde, a literatura analisada denota que, entre 1995 e 2008, 20% dos medicamentos 
oncológicos em estudo possuiam uma AIM aprovada pela FDA ou pela EMA, mas não 
por ambas. De igual modo, o conteúdo do resumo das caracteristicas possuía 
importantes diferenças em 28% do conjunto de medicamentos com AIM aprovada nos 
dois territórios. Finalmente, existem vários exemplos de decisões distintas no que se 
refere a acções regulamentares derivadas de questões de segurança num contexto pós- 
AIM, alguns dos quais particulamente mediáticos, como é o caso da rosiglitazona.  
Por outro lado, importantes desenvolvimentos regulamentares tiveram lugar no contexto 
da farmacovigilância, quer no território dos Estados Unidos da América, em 2007, quer 
na União Europeia, em 2012. Estas alterações legislativas pretendiam, entre outros 
objectivos, dotar as referidas agências de mais recursos e de um maior poder de 
decisão, implementando, ao mesmo tempo, um conjunto mais rigoroso de 
requerimentos e obrigações para a indústria farmacêutica/para os detentores de AIM.  
Perante este cenário de alterações legislativas e na ausência de uma recente análise 
das acções regulamentares derivadas de questões de segurança para um conjunto mais 
abrangente de medicamentos, este estudo foi proposto. 
A elaboração desta tese possui como objectivo o estudo, análise e discussão das 
acções regulamentares derivadas de questões de segurança entre 2010 e 2015, nos 
Estados Unidos da América e na União Europeia. Paralelamente, propõe-se a 
considerar a frequência, o timing após a AIM ter sido concedida e a natureza destas 
mesmas acções regulamentares, bem como a analisar quais as áreas/classes 
terapêuticas com maior número de acções regulamentares derivadas de questões de 
segurança. As actividades regulamentares da EMA e da FDA, bem como as decisões 
em estudo, serão comparadas e analisadas, visando reflectir-se sobre a aparente 
reduzida harmonização na avaliação de medicamentos e produtos de saúde entre estas 
duas autoridades. Por fim, de modo a ilustrar as diferenças descritas, é apresentado um 
caso de estudo de um medicamento associado a uma recente discussão de segurança, 
e do conjunto de acções regulamentares tomadas em ambos os territórios. 
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Um estudo/descrição abrangente da história, estrutura organizacional, processos e 
missão das autoridades reguladoras em questão foi efectuado. As diferenças 
substânciais entre a FDA e a EMA no que se refere às atividades de farmacovigilância 
e acções regulamentares em função de questões de segurança foram igualmente 
analisadas. Simultaneamente, procurou-se estabelecer pontos de convergência no que 
respeita às responsabilidades e objectivos propostos, e ilustrar as múltiplas iniciativas 
de importante colaboração entre as agências destas duas regiões.  
Para a análise das acções regulamentares foram consideradas (i) as comunicações 
dirigidas aos profissionais de saúde (Direct Heathcare Professional Communication - 
DHPC) publicadas em Portugal, no Reino Unido e as Dear Health Care Professional 
(DHCP) Letter nos Estados Unidos da América e (ii) as revogações de AIM em 
medicamentos comercializados na União Europeia em associação aos medicamentos 
retirados do mercado nos Estados Unidos da América por questões de segurança. 
Os resultados obtidos indicam um maior recurso às comunicações dirigidas aos 
profissionais de saúde nos países da União Europeia que nos Estados Unidos da 
América, no período entre 2010 e 2015. A disseminação dos riscos de segurança 
associados aos produtos comercializados nos Estados Unidos da América decorre, de 
acordo com dos dados disponíveis, através de outras ferramentas de informação 
comunicação de risco, actualmente disponíveis para a FDA.  
Dentro da globalidade dos dados analisadas, as pequenas moléculas apresentaram 
quer um maior número de comunicações de segurança, quer uma maior frequência de 
revogação/suspensão de AIM por razões de segurança. Por outro lado, os eventos 
adversos relacionados com os distúrbios cardíacos surgem como um dos principais 
impulsionadores das acções de segurança para as pequenas moléculas. Os dados 
obtidos demonstram ainda uma necessidade crescente de enfoque no que concerne a 
questões de segurança devido a erros de medicação. Resultados estes suportados 
pelas conclusões presentes na literatura actualmente publicada. 
De igual modo, as notificações espontâneas de reacções adversas a medicamentos 
continuam a representar a maior fonte de informação de segurança desencadeadora de 
de comunicações dirigidas aos profissionais de saúde como acção regulamentar em 
todos os países analisados. Todavia, verifica-se uma crescente utilização de dados de 
ensaios clínicos e estudos epidemiológicos tanto na identificação, como na avaliação de 
problemas de segurança, o que sugere um real incremento da importância dos mesmos 
no universo da farmacovigilância. 
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Finalmente, no que diz respeito ao timing das acções regulamentares, 66,6% das 
revogações de AIM por questões de segurança tiveram lugar até 5 anos após a 
aprovação da AIM, enquanto que 50,4% das comunicações dirigidas aos profissionais 
de saúde foram emitidas até 6 anos após a aprovação da AIM. 
O caso de estudo escolhido versou sobre as recentes discussões de segurança 
relativamente ao ácido valpróico (e derivados) e sua utilização em crianças, mulheres 
de idade fértil e grávidas, nomeadamente face aos riscos de malformações congénitas, 
alterações estruturais graves e importantes efeitos neurológicos adversos nestas sub-
populações. O contexto da utlização destes medicamentos foi descrito e as 
recomendações/acções regulamentares da FDA e EMA, bem como de algumas 
autoridades nacionais de estados membros da União Europeia, apresentadas. Os 
diferentes mecanismos e estruturas nos processos de farmacovigilância implementados 
e os instrumentos/medidas de minimização de risco disponíveis para cada uma das 
entidades reguladoras parecem justificar as diferentes recomendações e decisões 
observadas. Por outro lado, observam-se importantes dissemelhanças na estrutura e no 
conteúdo do resumo das características do medicaments/folheto informativo nestas 
duas regiões. 
Pela observação dos aspectos em estudo conclui-se que a análise e contextualização 
do quadro legislativo e do conjunto de processos e procedimentos actualmente 
disponíveis para a FDA e para a EMA é fundamentar no entendimento das decisões 
regulamentares e nas recomendações face a questões de segurança de medicamentos. 
A familiardidade com estes conceitos poderá promover uma maior sensibilização e 
entendimento, não só dos profissionais de saúde, mas também dos doentes e da 
população em geral, quer no que tange às avalições de medicamentos aquando do 
pedido de AIM, quer no que se refere às análise de dados de eficácia, qualidade ou 
segurança, que suportam a gestão de sinais, as alterações no conteúdo do resumo das 
característica do medicamento/folheto informativo, a implementação de medidas 
adicionais de minimização de risco e as decisões de revogação/suspensão de uma AIM. 
Verificou-se ainda que a natureza dinâmica dos processos regulamentares no âmbito 
da farmacovigilância permanece bastante atual, pelo que a necessidade de colaboração 
permanente entre os múltiplos intervenientes é fundamental na redução da duplicação 
de esforços e no suporte dos processos de avaliação, concessão e manutenção das 
AIM, em benefício dos reguladores, indústria farmacêutica e particularmente dos 
doentes. 
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Summary  
The natural history of approved drugs comprehends the discovery of new and important 
safety information in the post-marketing setting. In fact, studies show that for 9 to 25% 
of the drugs analysed, national or regional regulatory authorities required a safety-related 
regulatory action after their approval. Over the years, these publications have analysed 
safety-related regulatory actions, mostly on specific settings, such as for particular drug 
groups (e.g. biologicals, orphan medicines and exceptional circumstances/ conditional 
(accelerated) approval procedures) or individual countries.  
On the other hand, although current FDA and EMA guidance are driven by similar 
objectives regarding the identification, monitoring and minimization of risks, commonly 
leading to generation of similar data needs, there are cases where the two regulatory 
agencies have recommended distinct regulatory actions in response to the same safety 
issues identified. Substantial differences have also been identified with regards to risk 
communication and in monitoring implementation of risk minimization measures. 
Therefore, this study proposes to discuss and characterize the regulatory framework of 
pharmacovigilance activities within the European Union region and the United States of 
America, and analyse and compare the safety-driven regulatory actions for medicinal 
products, both small molecules and biologics, between the years of 2010 and 2015, 
following updates in applicable regulations in 2007 (for the US) and in 2012 (for the EU). 
The frequency, timing and nature of such regulatory actions evaluated, as well as the 
most impacted therapeutic groups. The direct communications to healthcare providers 
disseminated in Portugal, United Kingdom and US and the requests of withdrawal of 
medicinal products in the EU and the US territories were considered when analysing 
safety-related regulatory actions. Such recommendations provided by the EMA and the 
FDA were used to discuss the apparent lack of consistency in the assessment of 
medicinal products by these regulatory bodies. Finally, a case-study of a drug whose 
safety profile has been recently under evaluation in both territories is presented, and the 
recommendations/safety-related regulatory actions taken described. 
The results suggest that direct communications to healthcare providers are more 
frequently distributed in the EU than the US, with the majority of the safety risks 
associated to marketed products in the US territory having been announced to HCP and 
the general public by other risk communication tools currently available to the FDA. Both 
safety driven direct communications to healthcare providers and withdrawals were more 
frequent for small molecule medicinal products. Additionally, the data retrieved supports 
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previous findings on differences having been shown to exist in the nature of the safety-
related regulatory actions for biologicals compared with small molecules. Cardiac 
disorders related AE appear as a leading trigger for safety-driven regulatory actions for 
small molecules. Evidence also suggests more efforts still need to be allocated for 
tackling medication error-related adverse events. Spontaneous reports continue to 
account for the majority of the source data for triggering safety driven direct 
communications to healthcare providers in all regions, but relevant findings originating 
from clinical trials and epidemiological studies were observed, supporting the increasing 
importance of these sources in identifying and evaluating safety issues. With regards to 
timing of regulatory action, 66.6% of the safety-related withdrawals were issued within 5 
years after approval, while 50.4% of the safety driven direct communications to 
healthcare providers were issued within 6 years after approval.  
The use of valproic acid in children, women of childbearing potential and potential and 
during pregnancy given the associated risks of congenital malformations, major 
structural abnormalities and serious neurodevelopmental effects was chosen as case 
study. The distinct set of regulatory actions taken might be justified by the structurally 
different pharmacovigilance implemented mechanisms and instruments available to 
regulators in each territory but also given the inconsistencies in both structure and 
content of the labelling information between EU and US territories and to some extent 
within in EU territories. 
Given the study performed, it is possible to conclude that the analysis and 
contextualization of the on legislative framework and processes of the FDA and the EMA 
is essential to understand the agencies regulatory decisions and recommendations. 
Dissemination of these may help improve overall awareness and allow for a better insight 
and understanding on matters of divergent drug approvals and post-marketing safety 
recommendations, either it being signal management activities, label updates, additional 
risk minimization measures and withdrawals/suspensions. The dynamic nature of 
regulatory processes for pharmaceuticals risk management is still present on today’s 
exciting pharmacovigilance landscape and future regulatory standardization and 
increased collaboration is necessary to further help in reducing redundancy and support 
the review/assessment processes for the benefit of regulators, pharmaceutical industries 
and the patients. 
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 Introduction 
1.1 Pharmacovigilance: the basics 
The origins of pharmacovigilance are traced back to a series of drug induced tragedies, 
such as sulphanilamide, thalidomide, practolol, benoxaprofen and oral contraceptives, 
which themselves (re)defined the purpose and scope of pharmacovigilance(1). In the 
past, the process of pharmacovigilance was often considered to begin only after a drug 
was authorised for use in every day clinical practice. Nowadays, however, it 
encompasses all safety-related activities beyond the point at which humans are first 
exposed to a new medicinal lproduct . 
The World Health Organization (WHO) defines pharmacovigilance as the science and 
activities relating to the detection, assessment, understanding and prevention of adverse 
drug effects or any other drug related problem(2). Such science is therefore, in its 
essence, a risk management process, a system used to monitor the safety of medicines, 
playing a substantial role in both public health and in ensuring protection of patients’ 
safety.  
The decision to approve a drug is based on it having a satisfactory balance of benefits 
and risks within the conditions specified in the product labelling(3), which is based on the 
information available at the time of approval. Nonetheless, due to the limitations of pre-
marketing studies/data, drug safety can only be regarded as provisional when a new 
medicine is first marketed as there is a need to collect more evidence arising from ‘real 
world’ use(1,3). Systematic medicine safety monitoring is therefore necessary to identify 
previously recognized and unrecognized adverse drug reactions (ADR) and to evaluate 
the safety and efficacy of medicinal products during clinical trials and in the post-
marketing period. 
In fact, the knowledge related to the safety profile of the product can change over time 
through expanded use in terms of patient characteristics and the number of patients 
exposed. In particular, during the early post-marketing period the product might be used 
in settings different from clinical trials and a much larger population might be exposed in 
a relatively short timeframe(2). Serious hazards are seldom identified during pre-
marketing clinical trials because sample sizes are almost invariably too small to detect 
them. In addition, the prevailing conditions of clinical trials – selected patients, short 
durations of treatment, close monitoring and specialist supervision – almost invariably 
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mean that they will underestimate the frequency of ADR relative to what will really occur 
in ordinary practice(1).  
Warnings or restrictions will therefore be added to the product label, or a drug may be 
removed from the market, because unexpected or greater than expected morbidity or 
mortality is identified only after a drug enters widespread use. The discovery of new 
adverse events in the post-marketing setting is part of the normal, natural history of 
approved drugs(4). And thus, timely identification of and response to drug-related risks 
become central to the mission of pharmacovigilance and the health authorities. 
As a matter of fact, the newly generated information for marketed medicinal products can 
have an impact on its benefit risk ratio, meaning that a detailed evaluation of the 
information generated through pharmacovigilance activities is important for all products 
to ensure their safe use. The benefit-risk balance can be improved by reducing risks to 
patients through effective pharmacovigilance that can enable information feedback to 
the users of medicines in a timely manner(1). Generally speaking, the process starts with 
identification of a possible hazard, which is then evaluated and investigated and, if 
necessary, a set of actions is then taken with a view to minimising the risk. Pregnancy 
prevention in users of thalidomide is an example of such a safeguard; monitoring white 
blood cell counts to detect agranulocytosis in users of the antipsychotic drug clozapine 
is another(5–7). Implementation of such risk minimization measures also requires tools 
for communicating with health care providers (HCP), patients and caregivers and a 
periodic assessment of effectiveness should be made as a final step.  
Moreover, the process is iterative itself as new evidence may emerge or the measures 
taken may turn out to be insufficient. In fact, several drugs, such as Bextra (valdecoxib 
for Stevens–Johnson syndrome), Rezulin (troglitazone for hepatotoxicity), Vioxx 
(rofecoxib for myocardial infarctions) and Lotronex (alosetron hydrochloride due to 
severe constipation and ischemic colitis) have ended up being withdrawn from the 
European Union (EU) and/or the United States of America (US) markets because of 
serious/emerging adverse events that were unknown or not fully characterized when the 
product was approved, changing the benefit-risk profile of these drugs(1,8–13).  
With regards to the regulatory requirements, the requisite and place for 
pharmacovigilance within medicines regulation may have only been widely recognised 
in the 1960s as a consequence of the thalidomide tragedy, however the science of drug 
safety has grown to become an essential component of today’s pharmaceutical 
regulatory environment. And, although the role and tasks of regulatory authorities include 
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public health protection and promotion of safe and effective use of medicines, both 
regulatory authorities and manufacturers/pharmaceutical companies are equally 
responsible for the safety of medicinal products they approve/produce and sell(1).  
The major emphasis on patient safety and safety monitoring are also reflected in current 
driving policies of all regulatory authorities worldwide, such as the US Food and Drug 
Administration (FDA) Strategic Priorities for 2014-2018 and the European Medicines 
Agency (EMA) Network Strategy to 2020 draft, bearing witness to the intimate 
relationship between regulatory science and safety(14,15).  
With no disregards to the safety monitoring during clinical trials and its importance within 
the legislative framework, the below regulatory analysis will essentially focus on the 
regulatory aspects of post-marketing safety surveillance for two the territories in 
discussion. 
1.2 Legislative framework: EU versus US 
Regulations and guidance concerning the development, production, marketing and sales 
of medicinal products involve paradoxical goals. Overall they must ensure that new and 
effective medical treatments reach the public rapidly while simultaneously providing 
protection from ineffective or even unsafe therapies and from predatory marketing 
practices that often tout unproven products to vulnerable patients(16). 
While in the EU these responsibilities are shared between the national competent 
authorities and the European Medicines Agency (EMA), in the US, these regulatory 
functions fall within the competences of the US Food and Drug Administration (FDA). 
1.2.1 Origins of the FDA 
The FDA is the oldest comprehensive consumer protection agency in the US Federal 
Government. Its origins can be traced back to the Patent Office around 1848, carring out 
chemical analyses of agricultural products, a function that the newly created Department 
of Agriculture inherited in 1862(17). 
Its modern regulatory functions began with the passage of the 1906 Pure Food and 
Drugs Act, which was endorsed in a law prohibiting interstate commerce in adulterated 
and misbranded food and drugs(17–19). The basis of this legislation rested on the 
requirements of product labelling rather than pre-market approval. Drugs, defined in 
accordance with the standards of strength, quality, and purity in the United States 
Pharmacopoeia and the National Formulary, could not be sold in any other condition 
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unless the specific variations from the applicable standards were plainly stated on the 
label(20). Following the therapeutic disaster of sulphanilamide elixir, the Food, Drug, and 
Cosmetic Act was signed on 1938. This new law brought cosmetics and medical devices 
under control, and it required that drugs were to be labelled with adequate directions for 
safe use. Moreover, it mandated pre-market approval of all new drugs, such that a 
manufacturer would have to prove to FDA that a drug was safe before it could be sold. 
It irrefutably prohibited false therapeutic claims for drugs, although a separate law 
granted the Federal Trade Commission jurisdiction over drug advertising(21).  
Later in 1962, the FDA’s mission was expanded by the Kefauver-Harris amendments 
that added the requirement that drugs be proven “effective” as well as safe, and placed 
strict controls on the use of investigational drugs(22). Regulations regarding drug safety 
oversight developed furthermore, in 1976, to include medical devices, once again 
following a therapeutic disaster in which thousands of women were injured by the Dalkon 
Shield intrauterine device (23,24).  
Changes in the role of the FDA have come rapidly in the past decades, shaped in part 
by political pressure and expanding federal regulations, consumer activism, and industry 
involvement, with regards to the increasing complexity of drugs and devices, but also 
given the growth of the pharmaceutical industry into a major economic force within the 
US territory. Moreover, patient advocacy groups have shown to have influenced 
lawmakers, such is the case of creating incentives to stimulate industry interests in 
developing orphan drugs,  and have played an instrumental role in the agency's 
development of accelerated techniques for drug approval, for example  for the 
management of HIV/AIDS (16,24).  
Other important amendments to Federal Food, Drug, and Cosmetic Act include the 
Orphan Drug Act (1983), with the objective to f facilitate and promote the development 
of medicines and biological products in the treatment of rare diseases; the Drug Price 
Competition and Patent Term Restoration Act, known as the Hatch-Waxman Act (1984), 
guiding the development of generic medicines through the implementation of an 
Abbreviated New Drug Application and a period of commercial exclusivity for generic 
medicines as well as patent extension for innovative medicines, and the Prescription 
Drug User Fee Act, dated to 1992, introducing a royalty system to speed up the FDA's 
evaluation times(25).  
The FDA Modernization Act, adopted by the Congress in 1997, also represents a major 
strengthening of the FDA's mission, aiming to improve the efficiency of the FDA without 
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compromising patient safety. It covers several aspects of FDA operations, including the 
development of a better cooperation with the main international regulatory bodies, mainly 
the EU and Japan; the introduction of an additional market exclusivity of 6 months for 
medicines studied in paediatrics; the implementation of the Fast Track procedure to 
accelerate access to the market for drugs that treat serious diseases; the creation of a 
public data bank for clinical trials; and the implementation of new standards in the 
demonstration of drug efficacy(26,27). 
Such developments were followed by the FDA’s publication of Innovation or Stagnation? 
- Challenge and Opportunity on the Critical Path to New Medical Products in 2004, which 
examines the critical path needed to bring therapeutic products to fruition, and how the 
FDA can collaborate in and facilitate the overall pharmaceutical industry process 
(laboratory – production – end use) to make medical breakthroughs available to those in 
need as quickly as possible(26). 
Nonetheless, it is the Food and Drug Administration Amendments Act (FDAAA), 
endorsed in 2007, which has had a pivotal role regarding the safety of medicines in the 
post-marketing setting and in the need for the FDA to develop an active safety 
surveillance system. In fact, this piece of legislation empowered the FDA with the 
authority to require labelling changes with respect to new safety information, as well as 
to request post-marketing epidemiology studies and risk evaluation and mitigation 
strategies (REMS) and clinical trials for new drugs approved under the Federal Food, 
Drug, and Cosmetic Act and for biological products. In addition, the FDAAA increased 
the requirements for registering clinical trials, the FDA’s resources for risk management 
activities for pre and post-marketing and its authority over the contents of direct-to-
consumer advertising, but also required the FDA to become more transparent on its 
processes, decisions and knowledge on drug related information and to improve its tools 
for risk communication to healthcare practitioners and the general public (4,28). 
Additionally, a consolidated website to provide post-market safety information to patients 
and HCP was to be established by the FDA(29). 
During these years, the Medicare Prescription Drug Improvement and Modernization 
Act, introducing an entitlement benefit for prescription drugs, through tax breaks and 
subsidies and the Paediatric Research Equity Act, allowing FDA requiring that sponsors 
conduct clinical research into paediatric applications for new drugs and biological 
products, were also passed(26).  
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Further in 2012, FDA’s authority and ability to protect and promote public health was 
expanded with the Food and Drug Administration Safety and Innovation Act. FDA was 
allowed to collect user fees from industry to fund reviews of innovator drugs, medical 
devices, generic drugs and biosimilar biological products and to increase stakeholder 
involvement within their processes, particularly by connecting to and recognizing the 
value of patient input to the drug development enterprise, the ‘Breakthrough Therapy’ 
designation was created, to help promote innovation and speed patient access to safe 
and effective products. Companies could now expedite the development and review of 
new drugs in case of preliminary clinical evidence which indicated the drug may offer a 
substantial improvement over available therapies for patients with serious or life-
threatening diseases. And finally, focus was given to enhancing the safety of the 
medicinal products supply chain(26,30).  
1.2.2 Status quo  
Currently the FDA’s jurisdiction encompasses most food products, human and animal 
drugs, therapeutic agents of biological origin, medical devices, radiation-emitting 
products for consumer, medical, and occupational use, cosmetics and animal feed(31). 
Its core missions include 1) protecting the public health by ensuring the safety, efficacy, 
and security of human and veterinary drugs, biological products, and medical devices; 
and by ensuring the safety of US food supply, cosmetics, and products that emit 
radiation; 2) regulating the manufacturing, marketing, and distribution of tobacco 
products to protect the public health and to reduce tobacco use by minors; 3) advancing 
the public health by helping to speed innovations that make medical products more 
effective, safer, and more affordable and by helping the public get the accurate, science-
based information they need to use medical products and foods to maintain and improve 
their health; and 4) safeguarding the security of the food supply and by fostering 
development of medical products to respond to deliberate and naturally emerging public 
health threats(32). 
As a whole, the United States Food and Drug Administration is the agency responsible 
for ensuring that prescription drugs marketed in the US territory are safe and effective, 
with both the Center for Drug Evaluation and Research (CDER) and the Center for 
Biologics Evaluation and Research (CBER) monitoring and reviewing the safety 
information throughout life cycle of the medicinal products, under the Office of Medical 
Products and Tobacco. 
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CDER’s mission is to protect and promote public health by helping to ensure that human 
drugs are safe and effective for their intended use, that they meet established quality 
standards, and that they are available to patients. As part of the FDA, CDER performs 
an essential public health task regulating over-the-counter and prescription drugs, 
including biological therapeutics and generic drugs(33). 
On the other hand CBER aims to ensure the safety, purity, potency, and effectiveness 
of biological products including vaccines, blood and blood products, and cells, tissues, 
and gene therapies for both the prevention/diagnosis and treatment of human diseases, 
conditions, or injuries. This centre envisions to facilitate the development, approval of, 
and access to safe and effective products and promising new technologies, but also help 
to defend the public against the threats of emerging infectious diseases and 
bioterrorism(34).  
1.2.3 US laws and regulations 
The laws of the United States are adopted by congress and organized by subject into 
the United States Code. The Federal Food, Drug, and Cosmetic Act and subsequent 
amending statutes are codified into Title 21 Chapter 9. However, new laws cannot be 
enforced until new regulations (‘administrative law’) are issued, which are reordered in 
The Code of Federal Regulations (CFR). The CFR therefore is a systematisation of the 
general and permanent rules published in the Federal Register by the Executive 
departments and agencies of the Federal Government, which has the force and effect of 
a law. Title 21 of the CFR is reserved for rules of the Food and Drug Administration and 
contains all regulations pertaining to food and drugs, including those which apply to 
orphan drugs (21 CFR, Part 316), investigational new drugs (IND) (21 CFR, Part 312) 
and adverse drug event reporting(4,35).   
Within pharmacovigilance, post-marketing reporting of adverse drug experiences are 
comprised in part 314.80, while section 312.32 addresses Investigational New Drug 
Safety Reports, and part 310.305 refers to records and reports concerning adverse drug 
experiences of marketed prescription drugs for human use without approved new drug 
application. Safety requirements and practices for biological products, on the other hand, 
are included in part 600.  
In addition to the regulations published in the Federal Register, the FDA is also equipped 
with a set of documents representing its current thinking on a particular subject. These 
guidance documents provide guidelines to the processing, content, and 
evaluation/approval of applications and also to the design, production, manufacturing, 
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and testing of regulated products. They also establish policies intended to achieve 
consistency in the Agency's regulatory approach and establish inspection and 
enforcement procedures. Most current available guidance on drug safety are depicted in 
the table below (Table 1): 
Table 1 - Current (April 2017) available Drug Safety FDA Guidance 
Title Status Publishing date 
Drug Safety Information - FDA's Communication to 
the Public 
Final 
Guidance 
02-03-2007 
Medication Guides - Adding a Toll-Free Number for 
Reporting Adverse Events  
Final 
Guidance 
08-06-2009 
Drug-Induced Liver Injury: Premarketing Clinical 
Evaluation 
Final 
Guidance 
29-07-2009 
Format and Content of Proposed REMS, REMS 
Assessments, and Proposed REMS Modifications 
Draft 
Guidance 
01-10-2009 
Post-marketing Studies and Clinical Trials - 
Implementation of Section 505(O)(3) of the Federal 
Food, Drug, and Cosmetic Act 
Final 
Guidance 
31-03-2011 
Medication Guides - Distribution Requirements 
and Inclusion in Risk Evaluation and Mitigation 
Strategies 
Final 
Guidance 
17-11-2011 
Post-marketing Adverse Event Reporting for 
Medical Products and Dietary Supplements During 
an Influenza Pandemic 
Final 
Guidance 
23-02-2012 
Classifying Significant Post-marketing Drug Safety 
Issues 
Draft 
Guidance 
08-03-2012 
Drug Safety Information - FDA's Communication to 
the Public 
Draft 
Guidance 
08-03-2012 
Safety Reporting Requirements for INDs and 
BA/BE Studies - Small Entity Compliance Guide 
Final 
Guidance 
19-12-2012 
Safety Reporting Requirements for INDs and 
Bioavailability/Bioequivalence Studies  
Final 
Guidance 
19-12-2012 
Safety Considerations for Container Labels and 
Carton Labelling Design to Minimize Medication 
Errors 
Draft 
Guidance 
23-04-2013 
Best Practices for Conducting and Reporting 
Pharmacoepidemiologic Safety Studies Using 
Electronic Healthcare Data Sets  
Final 
Guidance 
14-05-2013 
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Title Status Publishing date 
Safety Labelling Changes - Implementation of 
Section 505(o)(4) of the Federal Food, Drug, and 
Cosmetic Act 
Final 
Guidance 
30-07-2013 
Best Practices in Developing Proprietary Names 
for Drugs 
Draft 
Guidance 
28-05-2014 
Risk Evaluation and Mitigation Strategies: 
Modifications and Revisions Guidance for Industry 
Draft 
Guidance 
06-04-2015 
Over-the-Counter Paediatric Oral Liquid Drug 
Products Containing Acetaminophen  
Final 
Guidance 
04-08-2015 
Adverse Event Reporting for Outsourcing Facilities 
Under Section 503B of the Federal Food, Drug, and 
Cosmetic Act  
Final 
Guidance 
07-10-2015 
Safety Assessment for IND Safety Reporting 
Guidance for Industry  
Draft 
Guidance 
16-12-2015 
Safety Considerations for Product Design to 
Minimize Medication Errors Guidance for Industry 
Final 
Guidance 
11-04-2016 
FDA’s Application of Statutory Factors in 
Determining When a REMS Is Necessary Guidance 
for Industry 
Draft 
Guidance 
20-09-2016 
Providing Post-market Periodic Safety Reports in 
the ICH E2C(R2) Format (Periodic Benefit-Risk 
Evaluation Report) 
Final 
Guidance 
28-11-2016 
 
1.2.4 The novelty of the European Medicines Agency 
The evolution of European regulation of medicinal products (and medical devices) is, by 
contrast, much more recent, with significant changes after the formation of the EU in 
1993. Clinical trial applications are generally handled in the member state, whereas 
marketing applications are approved by state and/or central agencies in accordance with 
regulations set forth by the European Commission (EC). Formed in 1995, the EMA was 
created to harmonize processes in the member state regulatory agencies to reduce 
annual costs to drug companies as well as to eliminate competition-restricting regulation 
in sovereign states. However, the EMA does not oversee all drug approvals the way the 
FDA does in the United States, as there are different routes a drug can be approved 
(national, decentralised or centralised procedures), depending on multiple factors, which 
include its class and manufacturer preferences(36). 
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EU medicines legislation entails both the protection of public health and the creation of 
a single market for medicinal products. It is initially proposed by the European 
Commission, after which goes  through consultative and political processes, and 
emerges via the European Parliament to be put into force by the Commission. In 
principle, in cases ofapparent conflict with any national legislation, EU law takes 
precedence, which does not necessarily mean that national authorities cannot enforce 
additional requirements in their own territory(37). 
1.2.5 Legal requirements in the EU 
Historically, the legislation underpinning the centralised system of authorisation exists in 
the form of a Regulation – number 2309/93, articles 19–26. However, most of the other 
EU legislation of medicines is fact contained in a single Directive – 2001/83, Title IX, 
articles 101–108. Aside from these, Directive 2001/20 covering clinical trials– is also 
relevant in relation to pharmacovigilance for investigational drugs(37). 
On the other hand, the legal framework of pharmacovigilance for marketed medicines is 
provided for in Regulation (EC) No 726/2004 for centrally authorised medicinal products 
and in Directive 2001/83/EC with respect to nationally authorised medicinal products 
(including those authorised through the mutual recognition and decentralised 
procedures)(38). In addition, Commission Implementing Regulation (EU) No 520/2012 
on the performance of pharmacovigilance activities stipulates operational details in 
relation to certain aspects of pharmacovigilance to be respected by marketing 
authorisation holders, national competent authorities and the EMA. Additionally, the EMA 
has released good pharmacovigilance practice guidelines (GVP) in order to facilitate the 
performance of pharmacovigilance activities(38,39), which include modules covering 
major pharmacovigilance processes (GVP modules I to XVI) and product- or population-
specific considerations, such as the ones developed for vaccines and biological 
medicinal products. 
Table 2 - Current (November 2017) GVP modules provided by the EMA 
Title Status Effective Date 
Module I – Pharmacovigilance systems and their 
quality systems 
Adopted 02/07/2012 
Module II – Pharmacovigilance system master file 
(Rev. 2) 
Adopted 31/03/2017 
Module III – Pharmacovigilance inspections Adopted 16/09/2014 
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Title Status Effective Date 
Module IV –Pharmacovigilance audits (Rev. 1) Adopted   
Module V – Risk management systems (Rev. 2) Adopted 31/03/2017 
Module VI – Management and reporting of adverse 
events to medicinal products (Rev. 1) 
Adopted 16/09/2014 
Module VI – Collection, management and 
submission of reports of suspected adverse 
events to medicinal products (Rev. 2) 
Adopted 22/11/2017 
Module VI Addendum I – Duplicate management 
of suspected adverse event reports 
Adopted 22/11/2017 
Module VII – Periodic safety update report Adopted 13/12/2013 
Module VIII – Post-authorisation safety studies 
(Rev. 3) 
Adopted 13/10/2017 
Module VIII Addendum I – Requirements and 
recommendations for the submission of 
information on non-interventional post-
authorisation safety studies (Rev. 2) 
Adopted 09/08/2016 
Module IX – Signal management Adopted 02/07/2012 
Module IX – Signal management (Rev. 1) Adopted 22/11/2017 
Module IX Addendum I – Methodological aspects 
of signal detection from spontaneous reports of 
suspected adverse events 
Adopted 22/11/2017 
Module X – Additional monitoring Adopted 25/04/2013 
Module XV – Safety communication (Rev. 1) Adopted 13/10/2017 
Module XVI – Risk minimisation measures: 
selection of tools and effectiveness indicators 
(Rev. 2) 
Adopted 31/03/2017 
Module XVI Addendum I – Educational materials Adopted 16/12/2015 
 
Legislation passed in 2010, accompanied by an implementing regulation in 2012, and 
further amended later that year, strengthened and rationalised the pharmacovigilance 
system. This was achieved, on one hand, by providing a clear legal basis for different 
roles and responsibilities of the principal actors within the EU (notably the pharmaceutical 
industry and regulators), by directing the EMA to develop a more robust, harmonised 
and rapid decision making process, and by increasing the engagement of patients and 
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health care practitioners. It also allowed patients to report ADR directly to the competent 
authorities. 
The regulation called for a science-based integration of benefit and risk, ensuring that 
requirements are proportionate to risk and increasingly focused on proactive and 
planned solutions, but also aimed for a reduction on systems duplication, with greater 
efficiency and improved transparency. Overall, this new legal framework aimed to 
improve patient safety and public health through better prevention, detection and 
assessment of adverse events to medicines, for which the newly created scientific 
committee, the Pharmacovigilance and Risk Assessment Committee (PRAC) was 
fundamental(29,38–41).  
Other changes included a strengthened coordination at the EMA, particularly on 
pharmacovigilance inspections and audits across the EU, better funding via fees, and 
reinforced authorization requirements with increased efforts on pharmacovigilance. 
Examples of these are the need of risk management plans for all new medicines, with 
measurements of the effectiveness of risk minimization as applicable, and stronger 
requirements for safety and efficacy studies in the post-authorization phase. Marketing 
authorisation holders (MAH) were then also requested to submit post-market benefit–
risk reports (29,38–41). 
Later on, in 2013, the EC adopted an Implementing Regulation introducing a black 
symbol to identify medicinal products which are subject to additional monitoring, followed 
by aa Delegated Regulation on post-authorisation efficacy studies, in2014. Generally 
speaking, such additional studies could be required to address certain well-reasoned 
scientific concerns, which may have a direct impact on the maintenance of the marketing 
authorisation (MA) (38,39). 
Further developments comprise of Addendum I to Module XVI on educational materials 
published on December 2015 and the revision of the Safety Communication GVP 
module, in 2017, particularly with amendments to the template Direct Healthcare 
Professional Communication (DHPC) and DHPC Communication Plans(42).  
More recently, the final Module IX on signal management and its addendum and the 
revision 2 of Module VI were published and will both come into effect on November 2017, 
together with the new EudraVigilance functionalities and the requirements of application 
of the ICH-E2B (R3) guideline. New Product- or Population-Specific Considerations, 
namely on the paediatric population are also currently available for public 
consultation(42). 
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1.2.6 Common grounds 
Despite the organizational and processual differences here depicted, similarities can be 
easily drawn for these two major regulatory authorities, particularly in terms of aims and 
responsibilities: ensuring that high-quality, safe and effective medicines are made 
available to patients in a timely manner.  
The formal path of harmonization was initially lead by the International Conference on 
Harmonisation (ICH) in 1990, bringing together the regulatory authorities and 
pharmaceutical industry of the US, Europe and Japan to discuss scientific and technical 
aspects of drug registration. Today, the ICH continues to issue guidelines for the 
standardization of clinical practices and technical requirements for human drugs, 
including the establishment and management of quality control laboratories and the 
prompt dissemination of new information on serious adverse drug effects(43). Thanks to 
the communication platform/forum provided by the ICH, regulatory agencies have 
agreed to key changes in practice and regulations far faster than it would ever be 
possible otherwise, and pharmaceutical development within organisations is now 
possible on an increasingly global basis rather than regionally, to benefit of patients. 
Different projects within several international bodies have also been under development 
specifically for pharmacovigilance. In addition to ICH, collaborations have been forged 
within the WHO, the Council of International Organisation of Medical Sciences and the 
Drug Information Association. These organisations promote the global importance of 
post-marketing drug safety and provide a global platform for adverse event data 
collection, propose broad frameworks for post-approval safety activities, develop 
technical specifications for industry submissions to regulatory bodies around the world, 
and offer a forum for education and exchange of ideas(44). 
More recently, a relatively new International Coalition of Medicines Regulatory 
Authorities (ICMRA) is bringing together regulators from 22 countries, and the WHO as 
an observer, spanning across North America, South America, Europe, Asia and Africa. 
Unlike the more operational ICH, ICMRA is designed to construct strategic orientations, 
providing high-level advocacy and leadership. Currently, the group is focused on the 
pharmaceutical supply chain, international crisis management (e.g. Ebola, Zika 
outbreaks), mutual recognition of good manufacturing practices (GMP), pharmaceutical 
inspections and other more comprehensive topics on the use of generic medicines and 
pharmacovigilance activities(45–47). 
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In parallel to the described harmonization developments, there seems to be an 
increasing tendency towards collaborative efforts on patient safety between the FDA and 
the EMA, provided their similar objectives on the identification, monitoring and 
minimization of risks (48). Recently approved legislation and regulation by both parties 
has focused on increased transparency, a higher level of accountability, a rigorous 
scientific basis for post-marketing decision making, improved processes, and better 
funding for these activities(29). Such shared values provide another motivation for close 
collaboration. 
In fact, since 2003, the EMA and the FDA have been holding regular meetings in multiple 
cluster areas, focusednot only on biosimilars, oncological therapeutics, orphan 
medicines and paediatric drugs, but also on safety of medicines (44). Designed to 
complement, rather than replace each other international undertakings in 
pharmacovigilance, these initiatives aim to promote exchange of information on safety 
related issues and to provide advance notice of anticipated regulatory action, public 
information and communication prior to decision-making. Product-related risk 
assessments with a special emphasis on emerging safety concerns, policies, guidance 
documents and regulations are also typically exchanged during these meetings(49). 
Another practical example of proactive aligned approaches for drug safety surveillance 
are the requirements for REMS and Risk Management Plans (RMP). Over the last few 
years, regulatory authorities have been changing the emphasis from the reactive 
collection of safety data to a more proactive safety surveillance approach. Public scrutiny 
of regulatory bodies, on the other hand, has also increased the focus on 
pharmacovigilance with the downstream impact of increased regulatory requirements for 
the post-marketing use. A comparison study of FDA and EMA guidance for 
pharmaceutical risk management indicates a similarity in overall objectives with respect 
to identifying, monitoring and minimizing a risk and a good degree of synergy in 
respective tool kits. Both agencies allow flexibility in the determination of product-specific 
actions required, recognizing the dependency on differing adverse effects of potential 
concern. However, they do differ on elements such as monitoring of implementation of 
risk minimization activities and reporting time requirements(50). 
With regards to post-approval periodic reports reviewing cumulative safety information, 
FDA usually requests Periodic Adverse Drug Experience Reports (PADER), while EMA 
and other agencies adopted the periodic benefit-risk evaluation report (PBRER). The 
PBRER is based on the 2013 ICH guideline E2C (R2) and intends to promote a 
consistent approach to periodic post-marketing safety reporting among the ICH regions, 
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enhancing efficiency by reducing the number of reports generated for submission to 
regulatory authorities. Both report types share a similar philosophy, presenting (i) a 
comprehensive, concise and critical analysis of any new and/or emerging information on 
the risks and (ii) the benefit in the approved indications, to enable an appraisal of the 
product’s overall benefit-risk profile. This evaluation is designed to help ascertain 
whether further investigations are necessary and whether changes should be made to 
the approval or to the medicinal product’s labelling, particularly for serious, unexpected 
adverse events. As a matter of fact, the FDA accepts all three formats - the 
PADER/Periodic Adverse Experience Report, Periodic Safety Update Report (PSUR “old 
format”) and PBRER - to fulfil the post-marketing periodic safety reporting requirements 
as per applicable legislation and has recently published a guideline describing the 
procedures applicants should follow for different scenarios. However, the reporting 
intervals and regulatory environment in which these periodic safety report updates occur 
is not uniform worldwide, allowing considerable differences in terms of content(51–53).  
On what it concerns signal management activities, both agencies are essentially 
responsible for the frequent monitoring and evaluation of data accumulated within 
specific databases: the EudraVigilance (EMA) and FDA Adverse Event Reporting 
System (FAERS)/US Vaccine Adverse Event Reporting System, in addition to submitting 
reports of suspected adverse effects associated with medicinal products to VigiBase, the 
WHO global database of individual case safety reports. Moreover, both agencies 
maintain tracking tools for validated safety signals: the European Pharmacovigilance 
Issues Tracking Tool, CDER's Document Archiving, Reporting, and Regulatory Tracking 
System and CBER's Therapeutics and Blood Safety Branch's Safety Signal Tracking. 
Similar processes and working groups for analysing safety information are maintained, 
marketing authorisation holders  are often requested supplementary records and 
recommendations for regulatory action, such as labelling changes, risk management 
programs and enhanced public communication are issued as necessary, following in 
depth analysis of each safety topic. Transparency and public record keeping on potential 
safety signals are currently a key value for both agencies: each month EMA publishes 
an overview listing all safety signals discussed during the latest Pharmacovigilance Risk 
Assessment Committee (PRAC) meeting and the recommendations given for each of 
them, while FDA conducts regular, bi-weekly screening of the FAERS database, making 
available a quarterly report on the Adverse Event Reporting System Web site of any new 
safety information or potential signal of a serious risk identified by Adverse Event 
Reporting System within the last monitoring(54–62). Besides these, several other 
methods for communication of drug safety information, e.g. ‘MedWatch Alerts’, ‘DHCP 
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letters’, ‘Drug Safety Communications’ and ‘Safety & Availability (Biologics) 
Communications’ are easily retrieved from the FDA website(63).  
Innovative strategies on proactive safety surveillance programs also exist on both sides 
of the Atlantic, such as the US Mini-Sentinel/Sentinel Initiative, designed to improve 
active surveillance by better understanding and more accurately estimating the incidence 
of a given safety risk in a relevant population. In fact, regulatory impact of Mini-Sentinel 
pilot includes improved signal refinement and support to FDA actions, on labelling 
changes (or decisions not take action in case where existing labels and communications 
adequately describe benefits and safety risks) and on safety communications; by 
characterizing the distribution (e.g. age and sex) of health outcomes of interest and 
ongoing drug surveillance; and by identifying and characterising drug-use patterns 
across the United States(64). Examples of important actions taken include review of 
dabigatran(65), Rotavirus vaccine(66,67), olmesartan(68), influenza vaccine(69), and 
human papillomavirus quadrivalent(70). 
Within EU, the EU-ADR project aimed at computerized system detecting adverse drug 
reactions and thus supplementing spontaneous reporting systems, by exploiting clinical 
data from electronic healthcare records of over 30 million patients from several European 
countries (The Netherlands, Denmark, United Kingdom and Italy). In this project, a 
variety of text mining, epidemiological and other computational techniques was used to 
analyse the medical records in order to detect ‘signals’. Based on this system, the EU-
ADR Alliance was created - a collaboration framework for running drug safety studies in 
a federated manned, using extracted data from multiples European electronic healthcare 
record databases. The EMA has commissioned three studies so far regarding the use of 
oral contraceptives, the risk of cardiac valve disorders associated with the use of 
bisphosphonates, and the monitoring of the effectiveness of risk minimization in patients 
treated with pioglitazone-containing products(71–73). 
1.2.7 Points of departure 
However, significant divergences within drug safety review and benefit-risk balance 
assessment of medicinal products remain. Despite ongoing attempts at international 
harmonisation described above, legislative requirements for the regulation of medicines, 
including for safety related topics, differ considerably around the world, resulting in 
multiple cases which are indeed well known for divergent regulatory decisions (28,74–
78).  
Safety driven regulatory actions from 2010 to 2015:  A comparative study between EU and US 
 
 30 
With regards to pre-approval, contrasts between FDA’s and EMA’s processes and 
regulations are plenty, with the most frequently addressed in published literature being 
time required for drug approvals and transparency of nonpublished drug trials 
data(16,79). In a recent article looking at the decision-making process for anticancer 
drugs at both EMA and FDA through a comparative qualitative study reporting directly 
the views, opinions, and experiences of regulators themselves, respondents provided 
various explanations for divergent regulatory opinions between EMA and FDA, 
particularly emphasising the different interpretation of the end points such as the 
progression-free survival as a measure of the clinical benefit. (80). 
In this same article, FDA respondents thought that their agency tended to approve 
broader therapeutic indications than the EMA, whereas EMA respondents thought to be 
more restrictive, limiting the indication to very specific patient populations. In fact, EMA 
respondents agreed that in EU, the more frequent use of therapeutic indications tailored 
on very specific patient populations could be related to country-specific reimbursement 
policies with only the selected patient population reported in the label being covered by 
the national health system(80). 
Still within oncology therapies, studies comparing the approaches of the EMA and the 
FDA in the evaluation and approval of new anticancer indications, found there were 
clinically relevant differences in therapeutic indications approved by the two agencies. 
An overall trend suggesting that the agency that was second in approving was usually 
more restrictive in the wording of the indication compared with the agency that provided 
first approval was also discussed(81). Comparisons have also been drawn for weight 
management therapies and anti-diabetic medicinal products(78,82).  
Several publications also address the possible relationship between delays in approval 
and a more refined assessment of safety, efficacy and risk/benefit(80,81,83–87). 
Potential risks of products that had a special review designation (fast track, accelerated 
approval and orphan designation) for both adverse efficacy (gefitinib) and safety 
(lapatinib) given the data emerged during their post-marketing periods are also 
extensively studied to date (84,86) 
Overall, disparities in drug approvals among regulatory agencies are attributed to 
differences in legislation and approval procedures, efficacy endpoints, disease activity 
indices, benefit/risk assessment, decision-making approaches and post-marketing 
requirements(74,78,80,83,84,86–96). 
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In the matter of post-approval safety surveillance, differences are also easily identifiable. 
For instance, pharmacovigilance planning is emphasized in the EU system, while a 
similar approach has not been formally adopted in the US. The detailed framework of 
post-approval safety studies and efficacy studies is different from that of post-marketing 
requirements for studies or clinical trials of a safety issue in the US. Additionally, there 
are also fundamental operational differences between the two agencies. In the EU 
system, scientific review is performed by experts within a decentralized network of 
national agencies, whose work is referred to a centralized committee, the 
Pharmacovigilance and Risk Assessment Committee. In the US, scientific review work 
is conducted within a single centralized agency, though there is no single body within the 
FDA that reviews each and every recommendation. 
Different interaction modalities with both industry and patients represent an additional 
source of divergence between the two agencies, with a potential impact on decision 
making(81). And finally, strategies of communicating risks to patients/healthcare 
providers and monitoring effectiveness of risk minimization measures implemented are 
unique for each system, as are reporting time requirements(81). 
1.3 Sources of information 
Accurately assessing the potential benefits and risks posed by a drug in the post-
marketing context requires the use of a wide variety of scientific data, including findings 
from clinical trials, epidemiologic and outcomes research, such as observational studies 
and meta-analyses, and post-marketing surveillance systems which detect and help to 
characterize adverse events. All sources of data - not only or primarily those obtained 
from clinical trials - have therefore the potential to contribute to sound regulatory 
decision-making(4). 
Monitoring product safety in the real word has been traditionally done by passive 
surveillance or the collection of spontaneously reported adverse events from healthcare 
providers and consumers following the administration of a medicinal product. 
Spontaneous reports play a major role in the identification of safety signals once a drug 
is marketed. In many instances, a company can be alerted to rare adverse events that 
were not detected in earlier clinical trials or other pre-marketing studies. Spontaneous 
reports can also provide important information on at-risk groups, risk factors, and clinical 
features of known serious adverse drug reactions(97). Several databases systems 
containing information on adverse events submitted to the health authorities are now 
available to support the agencies’ drug post-marketing safety surveillance programs 
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(VigiBase, Adverse Event Reporting System and Vaccine Adverse Event Reporting 
System and EudraVigilance)(12).  
Active surveillance, in contrast to passive surveillance, seeks to determine the complete 
number of adverse events via a continuous pre-organized process. Examples of active 
surveillance include sentinel sites, drug event monitoring and registries, such as follow-
up of patients treated with a medicinal product with a risk management programme. In 
general, it is more feasible to get comprehensive data on individual adverse event reports 
through an active surveillance system than through a passive reporting system(97). 
On another hand, traditional epidemiologic methods are also a key component in the 
evaluation of adverse events. There are a number of observational study designs that 
are useful in validating signals from spontaneous reports or case series, namely cross-
sectional studies, case-control studies, and cohort studies (both retrospective and 
prospective). Moreover, descriptive studies can too constitute an important component 
of pharmacovigilance, although not for the detection or verification of adverse events 
associated with drug exposures. These studies are primarily used to obtain the 
background rate of outcome events and/or establish the prevalence of the use of drugs 
in specified populations(97).  
Finally, when significant risks are identified from pre-approval clinical trials, further 
clinical studies might be called for, either to evaluate the mechanism of action for the 
adverse event, to determine whether a particular dosing instruction can put patients at 
an increased risk of adverse events or even which group of patients might be at an 
increased risk of adverse events, through genetic testing(97). 
1.4 Safety driven regulatory changes 
Approval of a marketing authorization signals the start of on-going evaluation of both 
benefits and risks during entire market life cycle of a drug. Regardless of the efforts to 
ensure drug safety before launch, it is the use of drugs in ‘real world’ setting which leads 
to the identification of new and important safety topics, often resulting in relevant safety 
driven regulatory actions. 
Early US studies suggested that 10% of drugs registered in the US between 1975 and 
1999 required a safety-related action(98,99). Another survey on drug safety 
discontinuations in the United Kingdom, the US and Spain, determined that 3 to 4% of 
all the drugs introduced in these countries were subsequently discontinued for safety 
reasons in at least one of the three countries. Therapeutic classes most commonly 
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associated with safety discontinuations were the nonsteroidal anti-inflammatory drugs, 
vasodilators and antidepressants(100). 
More recent data suggests that for about 10% of all marketed drugs, safety-related 
regulatory actions are required for new and serious safety issues leading to 
hospitalization, disability or even death(101). Research on Direct Healthcare 
Professional Communications in the Netherlands also concluded that 9% of all drugs on 
the market required a safety-related action(102). 
These safety issues may emerge both shortly after market entry and/or at a later stage 
in the drug’s life cycle(98,102,103), with half of all new black-box warnings appearing 
only after a drug has been under commercialization for around 12 years. In the US, half 
of the medicinal products with safety-driven withdrawals had remained on the market for 
5 years or more, while newly approved drugs have a one-in-three chance of acquiring a 
new black-box warning or being withdrawn for safety reasons within 25 years of 
approval(104). 
Studies have also been conducted for specific sub-groups of medicinal products. Orphan 
drugs granted marketing authorizations by accelerated approval, oncological products 
and products belonging to the anatomical main group of ‘Alimentary track and 
metabolism’ appear to have a higher risk for a safety-related regulatory action(103). 
With regards to biologics, literature suggests that approximately one out of four biologics 
approved in the US and/or the EU has required a safety-related regulatory action, defined 
as written communications to healthcare professionals and ‘black-box’ warnings, after 
granting of marketing authorization(105). Studies also show that biopharmaceutical 
products have a 14% probability of having an initial safety-related regulatory action within 
the first 3 years following market approval, with a higher risk of a safety-driven 
recommendations for the first biological products in each class(105). 
On the whole, above published figures illustrate the need for safety data to be gathered 
throughout the life cycle of a medicine due to the known limitations of clinical trials in 
predicting safety in ‘real-world’ use. By continuously collecting information once a 
medicine is available to the general public and taking action in response, regulators can 
ensure better public protection from emerging safety issues throughout a medicine's life 
cycle. Post-marketing research offers therefore a valuable and necessary complement 
to pre-registration studies in continuously evaluating the benefit-risk balance of marketed 
drugs.  
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Following identification of a new or important safety information, it is necessary to divulge 
such findings. Regulatory authorities and the pharmaceutical industry are, therefore, 
equipped with several different tools and strategies for if and when a safety issue 
emerges. Being able to communicate to both the public and healthcare practitioners 
about the safe use of medicinal products and about the risks associated to their use is 
key. 
On the one hand, labelling requirements are an essential part of the marketing 
authorisations both in the US and the EU, emerging as the basis of information for 
healthcare professionals and patients on how to use a medicine safely and effectively. It 
is hence crucial that labelling documents are kept updated throughout the lifecycle of a 
medicinal product, as new efficacy or safety data arise(106–108).  
Particular visual tools are available in each region. For instance, a warning is displayed 
in the US label and patient package as a framed box named ‘Black Box Warning’ which 
highlights particular serious or life-threatening potential safety issues of a prescription 
drug(109,110). In the EU, medicines under additional monitoring present a black inverted 
triangle displayed in their package leaflet and summary of product characteristics, 
helping to identify medicines, which are being monitored more intensively by the EU 
regulators. 
Additionally, agencies may wish to directly communicate a new important safety 
information to health care practitioners. A Dear Healthcare Professional letter (in the US) 
is a paper-based personalized mailing to healthcare professionals, the content of which 
should be agreed by the manufacturer of the drug and by the agency prior to their 
dissemination. In the EU, Direct Healthcare Professional Communications can be used 
to quickly disseminate key information to healthcare professionals. In the UK, for 
example, the national competent authority (NCA) additionally issues alerts, warnings and 
‘Drug Safety Updates’ to inform healthcare providers on new found risk, updates to 
practices and minimize patient harm(111). 
Finally, regulators also retain the authority to revoke marketing authorisation due to 
safety concerns. A medicinal product within the EU region can therefore be suspended 
and/or withdrawn from the market when the benefits of a drug no longer outweigh its 
risks(101). Similarly, the FDA can either revert to recalls or market withdrawals for the 
products under its supervision(112).  
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1.4.1 Labelling updates 
As previously mentioned, labelling is a crucial communication source to provide 
important safety information to both patients and healthcare professionals, and an 
integral part of the patients’ disease treatment/prevention.  
Within the EU territory, labelling requirements have been harmonized and are described 
in the applicable legislations(113,114). The summary of product characteristics (SmPC) 
is the basis of information for healthcare professional on how to use the medicine and 
needs to be included in the marketing authorization application for all EU medicinal 
products, thus being an intrinsic and integral part of the marketing authorization. The 
Package Leaflet (PL) is to be drawn up in accordance with the SmPC and contains all 
the information which is necessary and useful for the patient. 
In the US, the labelling constitutes a summary of essential scientific information needed 
for safe and effective use of the drug. It should be informative, accurate, and neither 
promotional in tone nor false or misleading, and should be based on data derived from 
human experience whenever possible. Medicinal product applicants are made aware of 
the requirements for the content and format of labelling for human prescription drug and 
biological products in both the Physician Labeling Rule (PLR) and Patient Counselling 
Guidance(107,108).  
One would expect that labels would not differ significantly among countries given that, 
at the time of granting marketing authorizations, regulatory authorities evaluate the same 
scientific data submitted by pharmaceutical companies. Additionally, labelling 
documents are kept updated throughout the lifecycle of a medicine as new efficacy or 
safety data emerge, which is again to be submitted to all necessary national competent 
authorities. However regulatory decisions impacting labelling documents also seem to 
be affected by the different local regulations and cultures(115). 
In fact, inconsistencies in doses, indications and overall safety profiles are known to exist 
among regions(88,105,116–122). These differences may arise from biological factors, 
such as pharmacokinetics and ADR incidence, which often show racial and gender 
differences(123–125). Nonetheless, more often than not, divergences in regulatory 
requirements, evaluation processes, healthcare systems and the general public’s risk 
perception emerge as factors that differentially impact the information included within 
labelling documents. Moreover, although package inserts contain information for the safe 
use of drugs, its format is not internationally standardized, and the structure and contents 
differ across countries. 
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One particular study on antineoplastic tyrosine kinase inhibitors found evidence that 
labelling for accelerated approval and priority review products was revised significantly 
more frequently than labels for traditional products. It was however unclear whether 
these updates were driven by new safety issues or for safety concerns already identified 
in the pre-approval phase. Given that these drugs are intended for the most serious of 
oncology settings with the highest unmet need, there may have been greater tolerance 
for any safety issues initially(84). 
1.4.2 Territory specific considerations: Box Warning and Black triangle 
list 
For medicinal products marketed in the US, a particular serious form of risk 
communication is available for when the FDA mandates that a set of clear warnings be 
highlighted at the beginning of the labelling material with a black box: 
 
Figure 1 – Black box warning from the Package Insert (Highlights of Prescribing Information) for DEPAKENE 
(valproic acid), AbbVie Inc. last updated on October 2017, available on 
https://dailymed.nlm.nih.gov/dailymed/  
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Figure 2 – Black box warning from the Package Insert (Full Prescribing Information) for DEPAKENE (valproic 
acid), AbbVie Inc. last updated on October 2017, available on https://dailymed.nlm.nih.gov/dailymed/  
 
This provision to be applicable to certain contraindications or serious warnings, 
particularly those that may lead to death or serious injury. On the other hand, these 
‘boxed warnings’ or ‘black box warnings’ (BBW) can be intended to highlight the dangers 
associated either with the use of individual drugs or with specific drug classes(110).  
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Clear guidance is provided by the FDA to the pharmaceutical industry for the boxed 
warning section of prescription drug labelling to be used to highlight one of the following 
situations(126): 
1) There is an adverse event so serious in proportion to the potential benefit from 
the drug (e.g. a fatal, life-threatening or permanently disabling adverse event) 
that it is essential that it be considered in assessing the risks and benefits of using 
the drug; 
2) There is a serious adverse event that can be prevented or reduced in frequency 
or severity by appropriate use of the drug (e.g. patient selection, careful 
monitoring, avoiding certain concomitant therapy, addition of another drug or 
managing patients in a specific manner, avoiding use in a specific clinical 
situation); 
3) The FDA approved the drug with restrictions to distribution/use to ensure safe 
usage (e.g. Approval with restrictions or REMS elements to assure safe use). 
Boxed warnings are ordinarily based on clinical data, but serious animal toxicity may also 
be give rise to a boxed warning(127). The BBW must briefly explain the risk and refer to 
more detailed information in the “Contraindications” or “Warnings and Precautions” 
sections, accompanied by the identifying number for the section or subsection containing 
the detailed information “WARNING” and other words that are appropriate to identify the 
risk in question(35,127). 
Published literature suggests boxed warnings are associated with more than one third of 
FDA-approved human prescription drugs, through a variety of therapeutic classes and 
commonly used across both inpatient and outpatient settings(128). Currently, there are 
934 marketed drugs with a boxed warning in place1.  
Analysis of safety labelling changes between 2005 and 2008 gathered BBW additions or 
revisions accounted for approximately 14% of these changes(129). Another set of data 
suggested that about 20% of approved chemical entities either acquire a BBW or are 
withdrawn from the market due to safety concerns up to 25 years from approval(98). 
Furthermore, because serious drug-related adverse events are more often a function of 
the pharmacologic class, most BBWs seem to be typically applied to all members of a 
given class(98,130,131). 
                                               
1 Micromedex export on 11-May-2017. 
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Other investigators reported a higher likelihood of post-approval black box warnings to 
labels for oncology drugs having received accelerated approvals compared with those 
which had regular approval (17% versus 9%). Additionally, of the four black box warnings 
added to the labels of oncology products with accelerated approval, three were only 
added more than 2 years after approval (84,85). 
Another study reported that BBW could be divided into 4 major categories of information: 
interactions (drug-drug, drug-disease), testing (baseline, ongoing), informational 
notifications (prescriber, dispenser, administrator, patient, third-party/registry), and 
‘‘nonactionable.’’ In such analysis, 37% of boxed warnings were classified as 
nonactionable and difficult to implement into health information systems, such as 
warnings included the risk of suicide associated with antidepressants and the risk of 
tendon rupture and tendinitis associated with systemic fluoroquinolones(132). 
Overall, the presence of a boxed warning on a prescription drug label currently presents 
multiple important regulatory and commercial implications. For example, administrative 
penalties are in place for facilities lacking safeguards against the inappropriate use of 
drugs with BBW and the addition of a new boxed warning could potentially be grounds 
for which the Centers for Medicare and Medicaid Services may institute new 
authorization criteria or even withdrawal of the drug from Medicare Part D 
formularies(128,132,133). Therefore, Simultaneously, BBW may influence if and how a 
medicinal product is prescribed, particularly when alternatives without BBWs exist. Such 
was the case of decline in sales for atypical antipsychotics following the labelling updates 
for increased mortality in dementia-affected elderly, but similar patterns are reported for 
other medicinal products (134–140). 
Alternatively, within the EU territory, a new concept of risk communication was 
introduced with the list of medicines under additional monitoring, following the updates 
to the pharmacovigilance legislation in 2012 (113,114).  
Such concept originates from the need to enhance the ADR reporting rates for newly 
authorised products for which the safety profile might not be fully characterised or for 
products with newly emerging safety concerns which also require to be better 
characterised. Its main goals are therefore to collect additional information as early as 
possible to further elucidate the risk profile of products when used in clinical practice and 
thereby informing the safe and effective use of medicinal products(141). An inverted 
equilateral black triangle as stipulated in the Implementing Regulation (EU) No 198/2013, 
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followed by an explanatory statement in the summary of product characteristics, makes 
these medicinal products readily identifiable. 
This list includes centrally and nationally authorised medicines in the following 
categories:  
• Medicines that contain a new active substance that was not contained in any 
authorised medicine in the EU on 1 January 2011; 
• Biological medicines authorised after 1 January 2011, including biosimilars; 
• Medicines for which the marketing-authorisation holder is required to carry out a 
post-authorisation safety study; 
• Medicines given conditional approval or authorised under exceptional 
circumstances and medicines authorised with specific obligations on the 
recording or monitoring of suspected adverse drug reactions. 
Medicinal products can be included on this list at the time of first time approval or at any 
time during its life cycle and shall remain under additional monitoring for five years or 
until the PRAC agrees such additional monitoring is no longer required. 
1.4.3 Communicating with Heath Care Professionals 
As already recognized, new or updated information about drug products emerges 
throughout a product’s life cycle. For marketed products, there are occasions when it is 
important to communicate this information promptly to HCP involved in prescribing or 
dispensing a drug or in caring for patients who receive a drug. Such direct safety 
communications concern important new information on an authorised medicinal product, 
which may have an impact on its risk-benefit balance and its conditions of use(142). 
As per the EU regulatory framework, a direct healthcare professional communication 
(DHPC) refers to a communication intervention by which important safety information is 
delivered directly to individual healthcare professionals by a marketing authorisation 
holder or a competent authority, to inform them of the need to take certain actions or 
adapt their practices in relation to a medicinal product. The preparation of DHPC involves 
cooperation between the marketing authorisation holder and the competent authority and 
an agreement between these two parties regarding to the content of the DHPC and the 
communication plans, including the intended recipients, the timetable and the channels 
for disseminating the DHPC. Additionally, where there are several marketing 
authorisation holders of the same active substance and/or a class of products for which 
a DHPC is to be issued, a single consistent message should be delivered. 
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GVP module XV also describes the specific situations when a DHPC should be 
disseminated given the need to take immediate action or change current practice in 
relation to a medicinal product:  
• Suspension, withdrawal or revocation of a marketing authorisation for safety 
reasons; 
• An important change to the use of a medicine due to the restriction of an 
indication, a new contraindication, or a change in the recommended dose due to 
safety reasons; 
• A restriction in availability or discontinuation of a medicine with potential 
detrimental effects on patient care.  
Other situations where dissemination of a DHPC should be considered are also stated: 
• New major warnings or precautions for use in the product information;  
• New data identifying a previously unknown risk or a change in the frequency or 
severity of a known risk; 
• New evidence that the medicinal product is not as effective as previously 
considered;  
• New recommendations for preventing or treating adverse events or to avoid 
misuse or medication errors with the medicinal product;  
• Ongoing assessment of an important potential risk, for which data available at a 
particular point in time are insufficient to take regulatory action. 
Further provisions on the principles and means of safety communication as well as 
guidance on the coordination and dissemination of safety communication within the EU 
network are described in the newly amended GVP Module XV – Safety communication, 
including annexes for the revised Direct Healthcare Professional Communication 
(DHPC) and DHPC Communication Plan templates. 
Finally, a competent authority in EU may disseminate or request the marketing 
authorisation holder to disseminate a DHPC in any situation where the competent 
authority considers it necessary for the continued safe and effective use of a medicinal 
product. 
A recent study reported that EMA does not currently display a publicly available list of 
safety driven DHPC issued. Furthermore, among the top 10 highest prescribing EU 
countries, only four (France, Netherlands, Spain and the United-Kingdom) currently 
make such DHPC publicly available since 2001, while some other countries (e.g. 
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Germany, Belgium or Sweden) have only recently begun to display on their website 
information regarding DHPC(143). With regards to Portugal, the national competent 
authority maintains available in its website the list of DHPC distributed since 2009.  
The same study also concluded there were substantial inconsistencies in the safety 
communications made available for newly authorized medicines, between the studied 
countries. Although the impact of these differences could not be assessed, authors 
suggested it raised questions about safety policies and regulatory efficiency and could 
possibly confuse patients and physicians(143).  
An equivalent term for safety communications is also present in the US regulations. As 
per the FDA Guidance, Dear Health Care Provider (DHCP) letters consist of 
correspondence ― often in the form of a mass mailing from the manufacturer/distributor 
of a human drug or biologic or from the FDA. DHCP letters may also be distributed by 
email and are often made available on the Internet (e.g. on company web sites or through 
patient advocacy groups)(142).  
Within US territory, information relates to an important safety concern that could affect 
the decision to use a drug or require some change in behaviour by HCP, patients or 
caregivers in order to reduce the potential for harm from a drug. Some DHCP letters are 
written as part of REMS communication programs to inform intended target audiences 
about the implementation of a new or modified REMS or to present additional safety 
information about the product(142). On the other hand, a DHCP letter can also provide 
information on how to improve the effectiveness of a drug or drug shortage issues 
updates, or may be even needed to correct misleading information in advertising or other 
types of prescription drug promotion.   
Regardless of the purpose, the FDA encourages manufacturers to consult with the 
appropriate review division, in order to discuss and determine whether a DHCP letter 
should be used, the target audience and the time frame for its distribution.  Additionally, 
recommendations on how to organize information to ensure effective and formatting 
techniques to improve accessibility are provided(142). 
The US regulation describes three types of DHCP letters(144), providing examples of 
model letters: 
• Important Drug Warning Letter - used to convey important new safety information 
that concerns a significant hazard to health and therefore could affect the 
decision to use a drug or require a change in behaviour concerning use of the 
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drug. This type of DHCP letter is used to convey information that is being 
incorporated into one or more of the following sections of the prescribing 
information: Boxed warnings, contraindications or warnings and precautions. 
• Important Prescribing Information Letter - used to convey important changes to 
the prescribing information other than those changes that are described in an 
Important Drug Warning letter. These are usually used to convey important 
changes to both the ‘Indications and use’ and ‘Dosage and administration’ 
sections of the prescribing information. 
• Important Correction of Drug Information Letter - intended to correct false or 
misleading information or other misinformation in prescription drug promotional 
labelling and advertising that is the subject of a Warning Letter2 or other FDA 
action. 
Despite of the different designations, regulation from both territories seem to aim towards 
the same goal of alerting physicians and other HCP about important new or updated 
information. An overview table is provided below for comparison purposes (Table 3).  
                                               
2 Defined by the FDA as correspondence that notifies regulated industry about violations that FDA 
has documented during its inspections or investigations. 
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Table 3 - Characterization overview of direct communication strategies with Health Care Providers in EU and US territories. 
 EU territory US territory 
How is it done? Via Direct Healthcare Professional Communication 
(DHPC) 
Via Dear Health Care Provider (DHCP) Letter 
Why/when is it needed? To inform HCPs of important safety information. 
 
This situation includes, but is not limited to: 
- Suspension, withdrawal or revocation of a 
marketing authorisation for safety reasons; 
- An important change to the use of a medicine due 
to the restriction of an indication, a new 
contraindication, or a change in the 
recommended dose due to safety reasons; 
- A restriction in availability or discontinuation of a 
medicine with potential detrimental effects on 
patient care.  
- New major warnings or precautions for use in the 
product information;  
- New data identifying a previously unknown risk or 
a change in the frequency or severity of a known 
risk; 
- New evidence that the medicinal product is not as 
effective as previously considered;  
- New recommendations for preventing or treating 
adverse events or to avoid misuse or medication 
errors with the medicinal product;  
- Ongoing assessment of an important potential 
risk, for which data available at a particular point 
in time are insufficient to take regulatory action 
To inform HCPs of important safety information 
 
This situation includes, but is not limited to: 
- Information that could affect the decision to use 
a drug or require some change in behavior by 
HCP, patients or caregivers 
- As part of REMS communication programs to 
inform intended target audiences about the 
implementation of a new or modified REMS or to 
present additional safety information about the 
product 
- To improve the effectiveness of a drug 
- To update on drug shortage issues 
- To correct misleading information in advertising 
or other types of prescription drug promotion 
How is it done? Cooperation and agreement between EMA/local HA and 
MAH with regards to: 
- Content of DHPC 
FDA encourages manufacturers to consult with the 
appropriate review division, in order to: 
- Discuss and determine whether a DHCP letter 
should be used 
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 EU territory US territory 
- Communication plans, including the intended 
recipients, the timetable and the channels for 
disseminating the DHPC 
- Determine target audience 
- Determine the time frame of distribution 
Are there different types? No Yes 
- Important Drug Warning Letter – in case of 
important updates to ‘Boxed warnings’, 
‘Contraindications’ or ‘Warnings and 
precautions’ sections of prescribing information 
- Important Prescribing Information Letter – used 
for important changes to both the ‘Indications 
and use’ and ‘Dosage and administration’ 
sections of the prescribing information 
- Important Correction of Drug Information Letter - 
intended to correct false or misleading 
information or other misinformation in 
prescription drug promotional labelling and 
advertising that is the subject of a Warning 
Letter or other FDA action 
Who is responsible for 
dissemination? 
MAHs Manufacturers 
Where can you access 
these? 
DHPCs may be available in NCA websites, as applicable 
for local territory 
DHCPs may be available on manufacturers/companies’ 
websites and sometimes patient support groups, but 
are not systematically available through FDA website 
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1.4.4 Recalls, suspensions and withdrawals 
Finally, regulators also retain the authority to revoke a marketing authorization due to 
post-marketing safety concerns, either through suspension and withdrawal from the 
market or resorting to recalls or market withdrawals. 
As per the applicable legislation, a recall is the removal or correction of a marketed 
product that the US Food and Drug Administration considers to be in violation of the laws 
it administers and against which the agency would initiate legal action, which can be 
conducted on the firm’s initiative, by FDA request or by FDA order under statutory 
authority. The following type of recalls are described under the CFR(112): 
• Class I – when there is a reasonable probability that the use of, or exposure to, 
a violative product will cause serious adverse health consequences or death. 
• Class II – when the use of or exposure to a violative product may cause temporary 
or medically reversible adverse health consequences or where the probability of 
serious adverse health consequences is remote; 
• Class III – when the use of or exposure to a violative product is not likely to cause 
adverse health consequences. 
On the other hand, a market withdrawal is described for when a product has a minor 
violation that would not be subject to FDA legal action. The firm removes the product 
from the market or corrects the violation. Additionally, medical device safety alerts can 
be issued in situations where a medical device may present an unreasonable risk of 
substantial harm(112). Industry guidance intended to assist those members of industry 
regulated by the FDA in handling all aspects of a product recall, including all corrections 
and removals, is available since 2011(145). 
Similarly, as per the EU regulations, EMA and national competent authorities may 
recommend suspending or revoking an authorization if(113): 
• The product proves to be harmful in the normal conditions of use; 
• Its therapeutic efficacy is lacking; 
• The risk-benefit balance is not favourable; 
• Its qualitative and quantitative composition is not as declared; 
• Certain conditions related to MA are not fulfilled.  
Additionally, products will be withdrawn from the European market in case (i) the above 
listed reasons are present, (ii) the controls on the medicinal product and/or on the 
ingredients and the controls at an intermediate stage of manufacturing have not been 
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carried out, (iii) and/or other requirements or obligations relating to the granting of the 
manufacturing authorisation have not been fulfilled(113).  
Since the 2012, marketing-authorisation holders of human medicines also have to notify 
EU regulators of any action to withdraw a product from the market, together with the 
reason for this action, when the decision is based on any of the above mentioned 
grounds (113,114,146,147), or when they intend to: 
• Temporary or permanent cease marketing of a medicinal product; 
• Suspend marketing of a medicinal product; 
• Withdrawn a medicinal product from the market; 
• Request for the withdrawal of a marketing authorisation; 
• Non-apply for the renewal of a marketing authorisation. 
Over the decades, drug regulatory agencies, pharmaceutical companies and various 
studies have reported drug withdrawals due to safety concerns. Initial publications 
suggested that drugs withdrawn or restricted represent a small proportion (about 1%) of 
marketed drugs, with 75 drugs/drug products having been removed from the market due 
to safety problems between 1969 and 2002(148). A more recent study reported that circa 
95 drugs were documented to have been withdrawn due to death as the primary reason 
between 1950 and 2013(148). However, not all of these drugs were withdrawn world-
wide. 
As a matter of fact, disparities in regulatory decisions between the regulatory bodies are 
often described. A study concluded that out of the 22 cases of drugs withdrawn due to 
safety concerns, between 1997 and 2005, in the US and EU, 10 presented a discrepancy 
in regulatory decisions/recommendations(149). Controversial debates resulting from 
these conflicting assessments are also well described in the literature (e.g. 
cyclooxygenase-2 inhibitors and glitazones)(119,150). 
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 Objectives  
Over the years, multiple studies have analysed safety-related regulatory actions, mostly 
for particular settings, such as for specific drug groups (e.g. biologicals, orphan 
medicines and exceptional circumstances/ conditional (accelerated) approval 
procedures) or individual countries (102,103,105,151). 
Data shows that between 9 to 25% of the drugs analysed required a safety related 
regulatory action by regulatory authorities after approval (102,152). An US study 
provided evidence that 10% of the drugs registered in the US between 1975 and 1999 
required a safety-related regulatory action. More recently, biologics have been 
associated with a 14% probability of requiring a first safety-related regulatory action 
within the first 3 years of being approved, with a higher risk of a safety related action in 
‘first-in-class’ biologics.  
In parallel, differences between EU and US regulatory frameworks and bodies are known 
and have been described to have led to divergent assessments, resulting in distinct 
regulatory actions (50,153). In fact, in spite of similar objectives and responsibilities, 
agencies do not always share the same interpretation of a medicinal product’s safety 
and efficacy data. Between 1995 and 2008, 20% of the oncological pharmaceuticals 
were approved by either the FDA or the EMA, but not by both, and 28% of approved 
drugs had significant variations in the label wording(154). Likewise, the safety review of 
approved drugs has also produced different safety-related regulatory actions(155). 
Considering the lack of an overall recent picture of safety-driven regulatory actions for 
medicinal products, both small molecules and biologics, particularly following the 
significant implications for pharmacovigilance activities emerging from the new legal 
frameworks in the US (2007) and in the EU (2012) an analysis of the safety-driven 
regulatory actions between 2010 and 2015, in either of these two territories was 
proposed. The aim of this study was to:  
• Determine the frequency, timing and nature of the safety related regulatory 
actions analysed; 
• Ascertain the most prevent therapeutically areas and molecule classes of the 
safety related regulatory actions analysed; 
• Compare regulatory activities and decisions between EMA and FDA; 
• Assess the apparent lack of harmony in addressing specific safety issues; 
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• And discuss the case of a particular chemical or biological entity exemplifying 
distinct safety related regulatory actions, between EMA and FDA. 
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 Safety Communication 
This section aims to perform an analysis on the determinants and nature of safety-related 
regulatory actions in the EU and US territories, for which direct communications to 
healthcare providers (DHCP letters/DHPC) have been distributed between the years of 
2010 and 2015. 
3.1 Materials and Methods  
Safety communications published in Portugal and the United Kingdom by the National 
Competent Authorities were used as direct communications to healthcare providers for 
the EU territory, given that no global list of DHPC is available for EU products. DHPC 
were identified from the websites of the National Authority of Medicines and Health 
Products, IP (INFARMED) in Portugal and the Medicines & Healthcare Products 
Regulatory Agency (MHRA) in the United Kingdom. All DHPC issued from 1 January 
2010 to 31 December 2015 in the United Kingdom and Portugal and available on the 
websites were included in this study.  
The FDA website was also searched for DHCP letters for the same period. Very few 
DHPC were available and the Division of Drug Information within the FDA’s Center for 
Drug Evaluation and Research was contacted in order to retrieve a list of DHCP letters 
distributed for the covering period. A response was received stating that no 
comprehensive database containing all DHCP letters is available for or maintained by 
FDA’s Center for Drug Evaluation and Research. An additional access to this data was 
submitted through the Freedom of Information Act. However, information was received 
that the FDA does not maintain a database with all Dear Health Care Provider Letters 
and that Companies are not required to provide FDA with such letters. Therefore the 
FDA website was screened to retrieve any other type of safety communication to HCP 
and/or the public containing safety-related regulatory actions for all the entries identified 
for the EU countries in study. 
The data extracted from DHPC included date of publication, International Non-
proprietary Names (INN) and safety issue described in the letter and the source 
triggering the safety publication (e.g. data originating from clinical trials, spontaneous 
ADR reports, epidemiological studies etc). Information on whether earlier DHPC had 
been distributed that same safety topic for a given drug or if the topic described 
concerned any special subset of patients (e.g. children, elderly, hepatic impaired or renal 
impaired patients) was also noted. The nature of the safety issue was classified 
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according to the Medical Dictionary for Regulatory Activities (MedDRA version 20.0) 
using System Organ Class (SOC). Furthermore, the time between the initial approval 
date (for the specific territory of DHPC publication) and DHPC was determined. Approval 
date was retrieved from EMA website for centralized approved products, and from 
Infomed - Base de dados de medicamentos (Medicine’s database from the Portuguese 
national competent authority for Medicines and Health Products)3 and electronic 
Medicines Compendium (eMC)4 websites for the remaining products with DHPC issued 
for Portugal or the UK, respectively. For DHPC issued within the USA, date of approval 
was retrieved from FDA Drugs@FDA database for FDA Approved Drug Products and 
DailyMed website5. 
The extracted data was summarized in Excel and populated according to the following 
variables: 
- Year (YY) and month (MM) of publication 
- Brand name 
- INN 
- Drug type: biological or small molecule 
- Anatomical Therapeutic Chemical (ATC) code and classification, both 1st level - 
anatomical main group (ATC I) and 4th level - chemical subgroup (ATC II) 
- Reason for DHPC to be distributed: safety topic, supply issue, quality issue, 
efficacy information or other 
- Safety topic description (by SOC) 
- Source: main source of the safety topic presented as per the DHPC. These could 
have originated from spontaneous reports, clinical trials, MAHs/EMA/NCA 
database analysis, epidemiological studies, pharmacokinetic studies, literature 
article(s), pre-clinical studies and quality control analysis, etc. 
- Type: US DHCP letters were further describer in terms of types as per US 
legislation, from ‘Important Drug Warning Letter’, ‘Important Prescribing 
Information Letter’ and ‘Important Correction of Drug Information Letter’ 
- Date of approval 
- Country of publication (PT, UK and/or US) 
- Action for US: corresponds to FDA set of actions (Yes/No) taken for entries 
originating for PT/UK DHPC, and its description, such as FDA statements, safety 
                                               
3 http://app7.infarmed.pt/infomed/inicio.php, accessed between Jan 2016 and Sep 2017. 
4 https://www.medicines.org.uk/emc/, accessed between Jan 2016 and Sep 2017. 
5 https://dailymed.nlm.nih.gov, accessed between Jan 2016 and Sep 2017. 
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labelling changes, drug safety alerts, drug safety communications and inclusion 
of boxed warnings for the specific safety concern in analysis, withdrawal or recall 
of the product and initiation of FDA requested studies. 
- Other: non-grouped information was also populated such us on whether previous 
DHPC had occurred for that same safety topic for a given drug or the topic 
described concerned any special subset of patients or a whole class of medicinal 
products. 
Where applicable, chi-square tests were used to assess associations. 
3.2 Results 
3.2.1 Characterization overview 
A total of 516 DHPC were identified from the data retrieved for the covering period 
studied. Of these, 223 DHPC were distributed in Portugal, 274 DHPC in the UK and 19 
DHPC in the United States of America. Screening and analysis of these 516 DHPC for 
overlapping of safety issues per INN or class with similar issue dates between any of the 
three regions identified a total of 364 ‘single’ DHPC.  
Of the 364 DHPC identified, 18 related to efficacy matters, namely changes in indications 
or new strengths, 56 concerned supply issues, such as market shortages or 
manufacturing site closures, and 27 referred to quality related communications with no 
reported adverse events, such as possible presence visible particles in parenteral 
solutions, sterility concerns or batch recalls due to vial defects. The majority however 
concerned safety related issues, adding to a total of 260 DHPC (71.4%). The remaining 
three letters include a name change, an error correction present in a previous label and 
the introduction of peel-off tracking labels (Figure 3).  
Similar safety distributions were found for DHPC issued in each of the studies countries: 
71.9 % in the UK, 68.4% in the US and 76.2% in Portugal (Figure 4). 
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Figure 3 - Rational for distribution of Direct Healthcare Professional Communications issued between 2010 
and 2015 in the UK, Portugal and the US 
 
 
Figure 4 - Rational for distribution of Direct Healthcare Professional Communications issued between 2010 
and 2015 per country studied 
 
With regards to the Anatomical Therapeutic Chemical (ATC) Classification System 
distribution of medicinal products with a DHPC, a total of 182 different ATC codes were 
retrieved, with the majority of the DHPC analysed belonging to the anatomical main 
groups of ‘Antineoplastic and immunomodulating agents’ (25.8%), ‘Antiinfectives for 
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systemic use’ (14.6%), ‘Blood and blood forming organs’ (11.5%) and ‘Nervous system’ 
(11.5%) (Figure 5). 
 
Figure 5 – Number of Direct Healthcare Professional Communications issued between 2010 and 2015 per 
anatomical main group (1st level of the WHO Anatomical Therapeutic Chemical (ATC) classification system) 
 
When segmented for safety related communications (260), the distribution was 
analogous, with 24.6% of the letters belonging to the anatomical main groups of 
‘Antineoplastic and immunomodulating agents’, 14.6% to ‘Antiinfectives for systemic 
use’, 12.7% to ‘Nervous system’ and 11.9% to ‘Blood and blood forming organs’ (Figure 
6).  
In respect of chemical subgroup for safety driven DHPC, the most recurrent classes 
included immunosuppressants (19), monoclonal antibodies (12), other drugs affecting 
bone structure and mineralization (08), protein kinase inhibitors (07), other 
immunosuppressants (06) and solutions for parenteral nutrition (06). Similar frequent 
chemical subgroups were identified when analysing the entire set of DHPC: 
immunosuppressants (20), monoclonal antibodies (14), other antineoplastic agents (09), 
other drugs affecting bone structure and mineralization (08), protein kinase inhibitors (07) 
and enzymes (08). 
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Figure 6 - Number of Direct Healthcare Professional Communications issued for safety-related reasons 
between 2010 and 2015 per anatomical main group (1st level of the WHO Anatomical Therapeutic Chemical 
(ATC) classification system)  
 
3.2.2 Regional distribution and overlapping DHPC 
From the published 516 DHPC, only one DHPC was issued in the three studied countries 
for the covering period. 
This safety communication concerned medication errors associated with the use 
rivastigmine transdermal system (Exelon Patch) – Annex I to III. Distributed in April 2010 
in both the UK and Portugal and later issued for the US as an ‘Important drug warning’ 
in September 2010, these communications describe the receipt of post-marketing 
reports of medication errors by the MAH associated with the use of rivastigmine patch 
some of which resulting in overdose. Exelon Patch was initially approved by the FDA in 
April 2000 and in May 1998 in the UK. 
Other eight DHPC for safety topics addressed both in UK and PT could be retrieved from 
the FDA website but DHPC did not include publication date (one) or where outside the 
studied interval (seven) and were not included in above data. For comparison purposes 
a brief analysis of these was however performed. Out of these eight, four concerned 
small molecules and the remaining four biological medicinal products, involving the 
following anatomical main groups: Antineoplastic and immunomodulating agents (03), 
Blood and blood forming organs (02), Alimentary tract and metabolism (01), 
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Antiinfectives for systemic use (01) and Nervous system (01). Safety topics addressed 
varied between Injury, poisoning and procedural complications SOC (03), Infections and 
infestations SOC (02), Cardiac disorders SOC (01), Congenital, familial and genetic 
disorders SOC (01), Metabolism and nutrition disorders (01), Nervous system disorders 
(01) and Vascular disorders SOC (01). 
A short description of the safety topics addressed in these six DHPC is presented below, 
with the exception of undated DHPC for rosiglitazone and cardiac events and DHPC for 
rituximab and the screening for hepatitis B virus before treatment. In fact, the DHPC 
issued for Portugal and UK (November 2013) concerned an update to the 
recommendation for hepatitis B virus screening, now recommended in all patients (not 
just those at risk of hepatitis B virus infection) before starting treatment with rituximab in 
all indications, while the US DHPC (July 2006) only referenced previous 
recommendations. Furthermore, despite DHPC for rosiglitazone pertained to its 
cardiovascular toxicity, safety communication for Portugal and UK (2010) concerned a 
clarification on the arrangements for the recall of rosiglitazone‐containing medicines from 
these markets following the recommendation by the EMA to suspend the marketing 
authorisation across Europe, while DHPC published in the US only summarized the 
major changes to the labelling for rosiglitazone and cardiovascular events.  
Risk of air embolism with the inappropriate use of spray devices administering fibrin 
sealant products 
Safety communications were issued both in Portugal and in the UK in August 2011 and 
then again in January 2013 for above mentioned life threatening risk. Latest DHPC 
presented a total of nine cases of air embolism (including three fatal cases) reported in 
association with fibrin sealants administered by spray application using a gas pressure 
regulator device. These events seem to be related to the use of the spray device at a 
higher-than-recommended pressure, and/or in too-close proximity to the tissue surface. 
The same safety issue had been communicated to HCP in the US in October 2009 in an 
Important Drug Warning. This concerned a post-marketing fatality report in association 
with the use of fibrin sealant (human), using a spray device at higher than recommended 
pressure and in close proximity to the surface of the tissue, received by the FDA. All 
letters included instructions to be followed when using a spray device for fibrin sealant 
application to prevent air or gas embolism. Additionally, in April 2010 and given the life-
threatening/potentially fatal consequences of air or gas embolism, the FDA 
recommended US prescribing information for fibrin sealant products to be updated to 
address this concern. No updates to PI were described in EU DHPC in either occasions 
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however the risk of life-threatening/fatal air or gas embolism with the use of spray devices 
employing a pressure regulator to administer fibrin sealants is adequately covered in the 
UK label(156). Fibrin sealant products were first approved in 1998 in the USA, later on 
in the UK in 2000 and in 2007 in Portugal. 
Mycophenolate mofetil and serious risk of teratogenicity 
A safety communication was sent out in November 2015 to HCP in both Portugal and 
the UK on strengthened advice for pregnancy prevention for both women and men when 
using mycophenolate mofetil. This DHPC described the new added to section 4.3 
Contraindications of the SmPC, which were added following a cumulative review of birth 
defects, following mycophenolate being confirmed as a powerful human teratogen. 
Evidence showed of an increased rate of congenital malformations and spontaneous 
abortions associated with mycophenolate in comparison with other medicines. On the 
other hand, in July 2015 safety labelling changes were approved by FDA/CDER in regard 
to embryofetal toxicity in the Warnings section, to pregnancy in the Prevention section 
and to the inclusion of congenital disorders on Post-marketing Experience, Adverse 
events section(157). The increased risks of first trimester pregnancy loss and of 
congenital malformations plus the change to pregnancy category D based on positive 
evidence of fetal risk observed in post-marketing data and from the US National 
transplantation pregnancy register had already been communicated to US HCP in an 
Important Drug Warning back in October 2007. Similarly, in 2007 and 2008 UK SmP for 
CellCept 1g/5ml powder for oral suspension was updated to include changes to sections 
4.6 Pregnancy and Lactation and 4.8 Undesirable Effects given the new data on 
congenital disorders and spontaneous abortions with mycophenolate mofetil(158). 
Mycophenolate mofetil was first approved in Portugal and the UK in 1996 and later on in 
1997 in the US. 
Natalizumab and Progressive Multifocal Leukoencephalopathy (PML) 
DHPC were issued both in Portugal and in the UK in February 2010 informing HCP of 
both the 31 cases of PML from approximately 66,000 people exposed to natalizumab up 
to January 2010 and of the apparent increase in risk with the duration of treatment. On 
the other hand, the US DHPC retrieved from FDA website dated from July 2006 detailed 
only 2 cases of PML but addressed the addition of a Boxed Warning to the Prescribing 
Information for the increased risk of PML with natalizumab therapy. Natalizumab was 
first approved in 2004 in the USA, later on in the June 2006 in the EEA. 
Stavudine and potentially severe side effects 
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In March 2011, DHPC were issued in Portugal and the UK concerning post-marketing 
safety reports and published literature on lactic acidosis, lipoatrophy and peripheral 
neuropathy. These resulted in a restriction of indications for stavudine and subsequent 
updates to the Product Information: sections 4.1 Therapeutic indications and 4.2 
Posology and method of administration to limit the duration of stavudine therapy to the 
shortest time possible. On the other hand, Important Drug Warning retrieved dated from 
2002 and described the potential for lactic acidosis as a complication of therapy with 
nucleoside analogues, including stavudine and its signs and symptoms. Current US 
Prescriber Information for ZERIT states nucleoside reverse transcriptase inhibitor for use 
in combination with other antiretroviral agents for the treatment of human 
immunodeficiency virus (HIV)-1 infection as indications for stavudine.  
Only one safety topic was addressed in both the UK and US DHPC issued during the 
covering period. In May 2013, UK HCP were informed of the potential risk for liver injury 
for tolvaptan and necessary product label updates, based on the results from further 
clinical trials investigating a different potential indication with long-term use of tolvaptan 
at higher doses than for the approved indication. Earlier that year, in January, the same 
had been communicated to US HCP through an Important Drug Warning letter. 
During the covering period, a total of three UK DHPC were found to be overlapping with 
one US DHCP letters, which had been distributed outside of the reporting period. These 
DHPC concerned leflunomide and the distribution of educational risk minimization 
materials in regard to risks of i) hepatotoxicity, including very rare cases of severe liver 
injury, which may be fatal, ii) hematotoxicity, including rare cases of pancytopenia, 
leukopenia, eosinophilia and very rare cases of agranulocytosis; iii) infections including 
rare cases of severe uncontrolled infections (sepsis), which may be fatal and iv) serious 
birth defects when administered during pregnancy, which were published in the UK on 
January 2011, May 2011 and June 2012. Within the US, an Important Prescribing 
Information letter had been distributed on October 2003 to inform HCP of the updates to 
the US labelling (Warnings - Hepatotoxicity and Immunosuppression Potential/Bone 
Marrow Suppression sections, Precautions - Laboratory Tests and Adverse events 
sections) based on the rare post-marketing reports of serious hepatic injuries and severe 
infections.  
On the other hand, whithin the studied period, one DHPC was identified concerning a 
safety topic overlapping for both Portugal and US territories. These safety 
communications addressed gadolinium-based contrast agents and the risk developing 
nephrogenic systemic fibrosis. In January 2011 Portuguese HCP were reminded of this 
Safety driven regulatory actions from 2010 to 2015:  A comparative study between EU and US 
 
 59 
risk and made aware both of the different classification (high, medium or low risk) of 
gadolinium-containing contrast agents established by Committee for Medicinal Products 
for Human Use (CHMP) based on the potential risk of developing nephrogenic systemic 
fibrosis but also on the changes to the prescribing information of these medicines, 
depending on the risk classification of the agents. In regard to the US, back in September 
2007 an Important Drug Warning had been issued to inform HCP of the revisions to the 
prescribing information gadolinium-based contrast agents based on post-marketing 
reports showing an increased the risk of the development of nephrogenic systemic 
fibrosis, namely the inclusion of a Boxed Warning and an update to the Warnings section. 
3.2.3 Drug type 
From the total data studied, DHPC were found to be more frequently distributed for small 
molecules (72.0%) than for biological products. Similarly, for safety-related DHPC, 
communications concerning small molecules were more frequently observed (76.9%) 
than the ones published for biological products.  
 
Figure 7 – Number of DHPC distributed by product type (biological vs small molecule) for the total set of 
DHPC retrieved and for safety-related DHPC only. 
 
3.2.4 Nature of Adverse events (AE) 
Safety-related DHPC published during the reporting period referred most often to 
adverse events under Injury, poisoning and procedural complications (16.2%), with 12 
DHPC concerning medication error related AE, and Cardiac disorders (13.1%) SOCs. 
With regards to small molecules, above mentioned SOCs were also the ones with most 
retrieved adverse events (17.3% for Injury, poisoning and procedural complications and 
16.1% for Cardiac disorders SOCs), while for biologicals they were most often classified 
under Immune system disorders (22.4%), Injury, poisoning and procedural complications 
(11.9%) and Vascular disorders (10.4%) SOCs.  
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Figure 8 - Number of safety-related Direct Healthcare Professional Communications mapped to MedDRA 
SOC as per the adverse drug reactions presented, per drug type (biological vs small molecule). 
 
DHPC published for small molecules were also significantly more frequent in most of the 
sub-grouped SOC analysis (Table 4), in comparison to the DHPC distributed for 
biologicals (chi-square=67.974 df=20, p<0.001). Cardiac disorders (chi-square=10.004, 
df=1, p=0.002) and Hepatobiliary disorders (chi-square=4.359, df=1, P=0.037) SOC-
related AE were significantly more frequent for small molecules safety communications, 
while Immune system disorders (chi-square=22.628, df=1, p<0.001) and 
Musculoskeletal and connective tissue disorders (chi-square=5.195, df=1, p=0.023) 
SOC-related AE were significantly more observed in DHPC distributed for biological 
products. Finally, product issues (chi-square=3.638, df=1, p=0.056) SOC-related AE 
were equally frequent in both class of medicinal products. 
Table 4 – Number of DHPC mapped by MedDRA SOC as per the adverse drug reactions present in the 
DHPC, per drug type (biological vs small molecule). 
MedDRA SOC  Biological Small molecule 
Blood and lymphatic system disorders 1 14 
Cardiac disorders6 1 41 
Congenital, familial and genetic disorders 0 12 
Eye disorders 2 5 
Gastrointestinal disorders 1 5 
                                               
6 SOCs with a significant statistical difference between biological and small molecules medicinal products. 
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MedDRA SOC  Biological Small molecule 
General disorders and administration site conditions 4 12 
Hepatobiliary disorders6 0 20 
Immune system disorders6 15 10 
Infections and infestations 4 7 
Injury, poisoning and procedural complications 8 44 
Investigations 0 1 
Metabolism and nutrition disorders 4 7 
Musculoskeletal and connective tissue disorders6 4 2 
Neoplasms benign, malignant and unspecified (incl 
cysts and polyps) 
3 13 
Nervous system disorders 1 13 
Product issues 5 5 
Psychiatric disorders 0 1 
Renal and urinary disorders 1 7 
Respiratory, thoracic and mediastinal disorders 3 5 
Skin and subcutaneous tissue disorders 3 13 
Vascular disorders 7 17 
Grand Total 67 254 
 
The majority of the safety communications identified for small molecules with AE 
reported under Cardiac disorders SOC was retrieved for medicinal products belonging 
to the main anatomical groups of alimentary tract and metabolism (24.4%), antiinfectives 
for systemic use (17.1%), cardiovascular system (17.1%) and antineoplastic and 
immunomodulating agent (14.6%) (Figure 9). 
 
Figure 9 – Anatomical main group distribution (%) for small molecule with safety-related DHPC with adverse 
drug reactions mapped to the Cardiac disorders MedDRA SOC 
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On another hand, for safety communications for small molecules and reporting AE 
related to hepatobiliary disorders, DHPC retrieved belonged mostly to the main 
anatomical groups of antineoplastic and immunomodulating agents (35.0%) and 
antiinfectives for systemic use (25.0%) (Figure 10).  
 
Figure 10 - Anatomical main group distribution (%) for small molecule with safety-related DHPC with adverse 
drug reactions mapped to the Hepatobiliary disorders MedDRA SOC 
 
Out of the seven DHPC retrieved for small molecules reporting hepatobiliary disorders 
in products of the antineoplastic and immunomodulating ATC class, four of these related 
to selective immunosuppressants chemical subgroup. Of the five DHPC retrieved for 
small molecules reporting hepatobiliary disorders in products of the antiinfectives for 
systemic use ATC class, four of these related to imidazole (03) and triazole (01) 
derivatives (data not shown). 
With regards to biological products and AE falling under the immune system disorders 
SOC, the vast majority of these safety concerns was retrieved for medicinal products 
belonging to either the main anatomical groups of antineoplastic and immunomodulating 
agents (46.7%), or antiinfectives for systemic use (40.0%) (Figure 11). Additionally, out 
of the seven DHPC retrieved for biological medicinal products reporting immune system 
disorders in products of the antineoplastic and immunomodulating anatomical main 
class, four of these referred to monoclonal antibodies chemical subgroup (Figure 12). 
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Figure 11 - Anatomical main group distribution (%) for biological medicinal products with safety-related 
DHPC with adverse drug reactions mapped to the Immune system disorders MedDRA SOC 
 
Figure 12 – Chemical group distribution (%) for biological medicinal products with safety-related DHPC with 
adverse drug reactions mapped to the Immune system disorders MedDRA SOC 
 
Similarly, for biological medicinal products and safety communications describing AE 
related to musculoskeletal and connective tissue disorders, 80% of the DHPC retrieved 
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belonged to the anatomical main group of musculo-skeletal system itself, all of which 
referring to chemical group of ‘Other drugs affecting bone structure and mineralization’ 
(data not shown). 
Finally, AE reported for product issues SOC were mostly prevalent for the following main 
anatomical groups: antiinfectives for systemic use (03), out of which two referred to 
biological medicinal products, cardiovascular system (02) and antineoplastic and 
immunomodulating agents (02). 
Table 5 – Anatomical main group and chemical group distribution (counts) for biological medicinal products 
with safety-related DHPC with adverse drug reactions mapped to the Product Issues MedDRA SOC 
ATC classification Biological Small molecule 
Antiinfectives for systemic use 2 1 
Encephalitis vaccines 1  
Triazole derivatives  1 
Vaccines 1  
Cardiovascular system  2 
Adrenergic and dopaminergic agents  2 
Antineoplastic and immunomodulating agents 2  
Gonadotropin releasing hormone analogues 1  
Interferons 1  
Nervous system  1 
Amides  1 
Sensory organs 1  
Antineovascularisation agents 1  
Blood and blood forming organs  1 
Solutions affecting the electrolyte balance  1 
Grand total 5 5 
 
3.2.5 Safety-related DHPC sources 
For the subset of studies products, multiple sources of data were identified having 
triggered a safety evaluation and/or on which the safety evaluation was performed, either 
by the MAH or NCA/Agency, and resulted in the publication of the DHPC.  
For DHPC pertaining to safety-related topics, the following sources were commonly 
mentioned in the DHPC or related source documents: Spontaneous Reports (63.8%), 
Clinical Trial (36.2%), Epidemiological study (9.6%), Literature (6.5%) and Pre-clinical 
(4.2%) (Figure 13). Some DHPC or source documents also presented safety information 
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originating from other sources, such as quality, name or packaging changes, updates to 
parental nutrition guideline, error corrections from the previous labelling and 
pharmacokinetic study. Such scenarios were captured as ‘Other’ (8.1%). Finally, for six 
DHPC, the absence of detailed data both in the letter itself and any associated 
documentation resulted in the grouping of source as ‘Company database’ (1.2%) and 
‘Health Authority database + Company database’ (1.2%). One DHPC also mentioned 
electrophysiological data, in addition to studies and post-marketing reports. When data 
involved three or more complementary sources these were classified as 
‘Comprehensive’. A total of 5.7% DHPC were classified as having ‘Comprehensive’ 
search, the majority of which including data analysis at least from clinical trials, literature 
and spontaneous reports (71.4%, data not shown). 
 
Figure 13 - Sources of data (%) for safety-related DHPC having triggered a safety evaluation and/or on 
which the safety evaluation was performed, either by the MAH or NCA/Agency 
 
Regarding the region of origin, around half of the data sources for the safety 
communications retrieved from both the EU (50.8%) and the US (46.4%) referenced 
spontaneous reports. Supporting data from clinical trials and epidemiological studies 
were more prevalent in the set of DHPC originating from EU than the DHCP letters 
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retrieved the US territory. Literature references and grouping under ‘Other’ were, on the 
other hand, more common for the DHPC published in the US. References to MAH or 
Health Authority databases, pharmacokinetics studies and pre-clinical data were only 
present for DHPC published in EU territory. Finally, in case of multiples sources classified 
as ‘Comprehensive’ data, all of the safety-related DHPC were retrieved either for 
Portugal or the UK, originating from either a in depth review from the EMA or from the 
UK NCA (Figure 14).  
 
Figure 14 - Sources of data (%) for safety-related DHPC having triggered a safety evaluation and/or on 
which the safety evaluation was performed, either by the MAH or NCA/Agency, presented by territory 
 
3.2.6 Non-overlapping DHPC 
A total of 238 ‘single’ safety communications were retrieved for topics for which DHPC 
were either published in Portugal and/or in the UK, but not in the US territory. Out of 
these, 53.4% could be linked to one or more of the following strategies used by the FDA 
for communication of safety risks or actions taken: Safety Labelling Changes (103), Drug 
Safety Communication (41), Drug Safety Alert (19), Safety Labelling Changes, including 
Black Box Warning (15), FDA Adverse Events Reporting System (02), FDA Statement 
(01), FDA Study (01) and Packaging Changes (01). 
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Figure 15 – Actions taken by the FDA (counts) for all the safety driven DHPC published either in Portugal 
and/or in the UK, but not in the US territory, for which another kind of safety communication/regulatory action 
was available from the FDA website. 
 
For the 111 EU DHPC no communication to HCP and/or to the public or any further 
action could be retrieved from the analysis of the FDA website. Out of these, 29.7% 
corresponded to products and/or formulations not marketed in the US territory. The 
majority of this products were to small molecules (76.9%), mostly belonging to the 
Antineoplastic and immunomodulating agents (19), Nervous system (09), Antiinfectives 
for systemic use (09) and Cardiovascular system (09) anatomical main groups (data not 
shown). 
For the remaining non-overlapping DHPC concerning medicinal products marketed in 
the US but with no identified safety communication/action, the safety topics more 
frequently reported belonged to Injury, poisoning and procedural complications SOC 
(08), Hepatobiliary disorders SOC (05), Cardiac disorders SOC (05) and Metabolism and 
nutrition disorders SOC (04) (Figure 16). Statistical significance was retrieved when 
comparing between EU DHPC with no identified US action (excluding EU DHPC for US 
non-marketed products) and EU DHPC with a indexed FDA action for Injury, poisoning 
and procedural complications SOC (Chi-square=6.846, df=1, p<0.01). The safety issues 
classified under this SOC concerned overdose (02), drug administration error (02), 
labelled drug-drug interaction medication error (01), product preparation error (01), new 
drug administration rate (01) and medication errors (01) (data not shown).  
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Figure 16 - Number of safety-related DHPC published in the EU region mapped to MedDRA SOC as per the 
adverse drug reactions presented for which there was no safety communication from the FDA. 
 
3.2.7 Timing of regulatory action 
For the subset of products studies, the median time between approval and the 
distribution of the DHPC was 13.7 years (globally), with an average of 11.0 years for 
biological medicinal products and of 14.7 years for small molecules. With regards to 
safety driven DHPC, the median time between approval and the safety communication 
was 11.7 (globally), with an average of 8.1 years for biological medicinal products and 
an average of 12.7 years for small molecules. Data shows 50.4% of the safety driven 
DHPC were issued within 6 years after approval. 
 
Figure 17 – Average time (years) between marketing authorization approval and distribution of DHPC 
regardless of reason (A) for all products types (pink), for small molecules (blue) and for biologicals (green); 
and distribution of safety-related DHPC (B) for all products types (pink), for small molecules (blue) and for 
biologicals (green). 
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3.3 Discussion  
Results from DHPC analysis indicate a more prevalent distribution of safety 
communications for safety driven topics. Such results are in line with the scope of the 
use of direct communications to healthcare providers, as per the local regulations and 
guidance for both the EU and the US. In this study DHPC were predominantly 
disseminated for small molecules. Although serious safety issues have been suggested 
to be more common with biological agents(105), the fact that small molecules still 
dominate the market may be here reflected in both the total number of DHPC and for the 
safety-driven subset analysis. 
Results also showed the majority of the safety driven DHPC belonged to the anatomical 
main groups of ‘Antineoplastic and immunomodulating agents’ (25.8%). Literature 
suggests that these drugs have been frequently associated with more safety driven 
regulatory actions(85,102). Additionally, the fact that these drugs are often used outside 
of their approved indication could also explain the higher frequency of safety related 
issues(85). 
Only one overlapping DHPC could be found for the covering period between the US, 
Portugal and the UK. The fact that there very few DHPC available through the FDA 
website may greatly contribute for this fact, as 53.4% of the DHPC published in Portugal 
and/or in the UK could be linked to one of the strategies used by the FDA for 
communication of safety risks in the covering period. Additionally, the exclusion of safety 
communications published outside of the covering period given the different timelines for 
identification, assessment and regulatory action between US and UE should also be 
considered. 
Safety-related DHPC referred most often to adverse events under Injury, poisoning and 
procedural complications (16.2%) and Cardiac disorders (13.1%) SOCs. Previous 
studies seem to support such distribution findings, at least in the Netherlands(102). The 
high frequency of Injury, poisoning and procedural complications SOC-related AE 
resulted from the 12 DHPC reporting medication error related AE. Medication errors are 
common around the globe(159) and responsible for considerable patient harm(160). In 
fact, the prevention of medication errors by healthcare professionals has gained 
particular interest in the last years, especially by the health authorities/regulators who 
have been developing strategies to minimise its potential risks (159,161,162).  
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Adverse events relating to the Cardiac and Hepatobiliary disorders SOCs were 
significantly more frequent for DHPC for small molecules, while Immune system and 
Musculoskeletal and connective tissue disorders SOC-related AE were significantly 
more frequently observed in DHPC distributed for biological products. Differences have 
been shown to exist in the nature of the safety-related regulatory actions for biologicals 
compared with small molecules(105). Published literature on DHPC and withdrawals for 
safety reasons reflect findings for small molecules(98,100,102,163), while research on 
biologicals approved in the United States and the European Union also retrieved 
comparable results for immune system disorders(103,105). The multiple safety 
communication on osteonecrosis of the jaw distributed for denosumab in 2014 and 2015 
account for the increased frequency of Musculoskeletal and connective tissue disorders 
SOC-related AE. 
Spontaneous reports accounted for around 50% of the source data for triggering safety 
driven DHPC in all regions. These findings seem to be in line not only with previous 
studies and the overall key role spontaneous reporting of adverse drug effects has had 
historically in the post-marketing surveillance(164,165), but also with recent data 
suggesting a positive correlation between spontaneous reports and different types of 
safety driven regulatory actions in Japan(166). On the other hand, clinical trials and 
epidemiological studies accounted for 45.8% of the data sources for safety-related 
DHPC. An increased use of case–control studies, cohort studies, randomized clinical 
trials and meta-analysis for the recent decade has also been reported in previous 
studies(167).  
Finally, high percentage of ‘Other’ as a source for DHPC published in the US can be 
explained by the publication of six DHPC for biologic products warning healthcare 
practitioners of the risk of allergic reactions with these products given the possible 
presence of natural rubber latex in the containers of influenza vaccines (02), hemophilus 
influenzae B vaccines (01), hepatitis vaccines (02) and pertussis vaccines (01), which 
may cause allergic reactions in latex sensitive individuals. These communications are a 
result of a FDA review of the “latex-free” claims made by MAHs, which concluded that 
the documentation provided by manufactures was inadequate to support such claim. As 
a result, the FDA mandated that the product information for such products be revised to 
include a warning that “the syringe tip caps may contain natural rubber latex, which may 
cause allergic reactions in latex-sensitive individuals.” 
The majority of the non-overlapping safety drive DHPC between EU and US could be 
linked to one of several strategies used by the FDA for communication of safety risks, 
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namely Safety Labelling Changes, some of which included Black Box Warnings, and 
Drug Safety Communications. Such findings appear to support the alignment on ideology 
and scope of action between the two regulators, particularly on actively monitoring, 
identifying and reviewing new important safety information in the post-marketing setting, 
in spite of the different set of regulatory tools available and resulting actions 
recommended. For the final non-overlapping safety communications mapped to Injury, 
poisoning and procedural complications SOC, it should however be noted that 60.0% of 
these were medication error AE associated with two specific products (levetiracetam and 
tacrolimus for oral administration). 
Finally, the average time between approval and publication of safety-driven DHPC was 
11.7 years (globally), with an average of 8.1 years for biological medicinal products and 
an average of 12.7 years for small molecules, ranging between less than one year to 28 
years. Published literature on safety communication of medicinal products also suggest 
that level of innovation is not clearly correlated with frequency and timing of serious 
safety issues that are identified post-approval(168). Taken together such evidence 
underlines the need for continuous close monitoring of the benefit-risk profile and risk 
management of medicinal products during their whole life cycle.  
 MA suspensions and withdrawals 
The following section aims to perform an analysis on the determinants and nature of 
suspensions and withdrawals, both for small molecules and biologic medicinal products, 
in the EU and US territories, between the years of 2010 and 2015. 
4.1 Materials and Methods  
The EMA and FDA websites were searched for all medicinal products withdrawn in the 
5-year period from 2010 to 2015. The data extracted included date of publication of 
withdrawal, INN and the reason for withdrawal. Information on whether earlier safety 
related actions, including suspension or previous assessments for the specific safety 
topic, had occurred for that given molecule was also retrieved from the relevant websites. 
Such safety concerns were classified according to the Medical Dictionary for Regulatory 
Activities (MedDRA version 20.0), using SOC level. Furthermore, the time between the 
initial approval date (for the specific territory) and the withdrawal was determined. 
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Approval date was retrieved from the EMA website, FDA Drugs@FDA database for FDA 
Approved Drug Products or DailyMed website7. 
The extracted data was summarized in Excel and populated according to the following 
variables: 
- Brand name 
- Drug type: biological or small molecule 
- INN 
- Anatomical Therapeutic Chemical (ATC) classification, both 1st level - 
anatomical main group (ATC I) and 4th level - chemical subgroup (ATC II) 
- Status of MA  
- Date of withdrawal/suspension 
- Reason for withdrawal: commercial, legal, lack of efficacy, quality or safety  
- Any other relevant information, including previous actions for same safety 
concern, such as recalled, suspended or recently assessed by the Health 
Authority for safety issues 
- Safety topic description (SOC) 
- Date of approval 
- HA recommending withdrawal from use (EMA and/or US) 
4.2 Results 
4.2.1 Characterization overview 
In the period of 2010 to 2015 a total of 91 medicinal products were found to have been 
withdrawn from use on either US and/or EU markets. These medicinal products 
corresponded to 67 different ATC codes and were mostly small molecules (71.4%). 
                                               
7 https://dailymed.nlm.nih.gov, accessed between Jan 2016 and Sep 2017. 
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Figure 18 – Distribution of withdrawals (%) for the covering period independently of trigger both 
recommended by the EMA and the FDA by product type (biological vs small molecule). 
 
Overall, the majority of the withdrawals occurred for commercial (71.4%) or legal reasons 
(19.8%), such as sunset clause. Remaining products withdrawn for safety concerns 
(5.5%), quality issues (1.1%) and lack of efficacy (1.1%).  
 
Figure 19 – Global distribution of withdrawals (%) for the covering period by reason. 
 
During the covering period, one marketing authorization was suspended in EU. This 
concerned MACI (matrix-applied characterised autologous cultured chondrocytes) and 
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the absence of an authorised manufacturing site, which precludes the satisfaction of the 
requirements in Article 41 of Directive 2001/83/EC(169). 
4.2.2 Regional distribution  
Results showed that 92.3% of the withdrawals only took place in the EU, the majority of 
which for commercial (77.4%) or legal reasons (20.2%). One medicinal products was 
withdrawn because of safety reasons and another due to lack of efficacy. In the US 
territory, the majority of the withdrawals were safety-driven (57.1%) (Figure 20).  
 
Figure 20 - Distribution of withdrawals (count) for the covering period both recommended by the EMA and 
the FDA by reason. 
 
Only one product was withdrawn in both the US and the EU markets during the covering 
period. Drotrecogin alfa (Xigris) is a recombinant version of the endogenous activated 
Protein C, produced by genetic engineering from an established human cell line. Xigris 
was indicated for the treatment of adult patients with severe sepsis with multiple organ 
failure when added to best standard care. The product was approved in the US in 2001 
and later in 2002 for the EU under exceptional circumstances. Following results of the 
PROWESS-SHOCK study, which showed the study did not meet the primary endpoint 
of a statistically significant reduction in 28-day all-cause mortality in patients with septic 
shock, the MAH announced a worldwide voluntary market withdrawal(170,171).  
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4.2.3 Safety-driven regulatory actions 
Withdrawals and suspensions for safety reasons (11) were mostly linked to Cardiac 
disorders (76.9%) (Figure 21). These concerned a total of eight different ATC codes, with 
most of the sub-grouped products analysed belonging to the anatomical main groups of 
‘Alimentary tract and metabolism’ (36.4%) and ‘Cardiovascular system’ (36.4%) (Figure 
22). 
 
Figure 21 – Withdrawals and/or suspensions (%) mapped to MedDRA SOC as per the adverse drug 
reactions presented, for the covering period in both territories. 
 
Figure 22 – Anatomical main group distribution (%) medicinal products with safety-related withdrawals and 
suspensions for the covering period in both territories. 
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4.2.4 FDA 
With regards to the US territory, four withdrawals took place due to safety concerns. A 
brief description on each safety driven withdrawal case is presented below, including 
actions take within the EU territory, as applicable. 
Sibutramine 
On October 2010, the FDA recommended against the continued prescribing and use of 
sibutramine (a serotonin-noradrenaline re-uptake inhibitor used in the management of 
obesity) given the newly identify risks on cardiovascular safety, and requested the 
manufacturer to voluntarily withdraw this product from the market. Such 
recommendations were made three years after the drug’s initial approval, and based on 
new data from the Sibutramine Cardiovascular Outcomes (SCOUT) trial, which 
demonstrated a 16% increase in risk of major adverse cardiovascular events, such as 
stroke or heart attack,  in patients treated with sibutramine compared to patients taking 
a placebo(172). Preliminary data on the same clinical trial had been under discussion by 
the EMA since November 2009. The CHMP noted that the use of sibutramine was not in 
accordance with the prescribing information for most of the patients enrolled in the 
SCOUT study, as sibutramine is contra-indicated in patients with known cardiovascular 
disease and that the treatment duration in the study was also longer than normally 
recommended. However, because obese and overweight patients are likely to have a 
higher risk of cardiovascular events, the Committee was of the opinion that the data from 
the SCOUT are relevant for the use of the medicine in clinical practice. Based on such 
findings, on January 2010, the CHMP concluded that the benefit/risk ratio for 
sibutramine-containing medicinal products was not considered favourable and 
recommended the suspension of the MA for the sibutramine-containing medicinal 
products(173).  
Propoxyphene 
Also in 2010, healthcare professionals were notified that the manufacturer had agreed 
to withdraw propoxyphene, an opioid pain reliever used to treat mild to moderate pain, 
from the US market at the request of the FDA. The regulator’s recommendation was 
based on the available data including findings from a new randomized clinical trial that 
showed significant changes to the electrical activity of the heart, such as prolonged PR 
interval, widened QRS complex and prolonged QT interval, even when propoxyphene 
was taken at therapeutic doses(174). EMA, on the other hand, had already completed a 
review of the safety and effectiveness of dextropropoxyphene-containing medicines on 
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2009, under an ‘Article 31’ referral. The EMA had concluded that the benefits of 
dextropropoxyphene did not outweigh its risks, and recommended that all marketing 
authorisations should be withdrawn throughout the European Union. Later on, at the 
request of the MAHs, the CHMP re-examined its opinion having confirmed its original 
recommendation that the marketing authorisations for the non-parenteral (tablets, 
capsules and suppositories) forms of dextropropoxyphene-containing medicines should 
be withdrawn. For the parenteral form (solution for injection), the CHMP recommended 
that the marketing authorisations be suspended until further data are available(174). 
Octagam  
Immune globulin intravenous (human) (Octagam) was initially granted MA in US in May 
2004 (175) and in September 2010 both the manufacturer and the FDA notified 
healthcare professionals that, a voluntary market withdrawal of all lots of Octagam 
currently in the US market was being initiated due to previously reported thromboembolic 
events with this medicinal product(176). In EU, an Urgent Union procedure (Article 107i 
referral) was initiated based on the decision of the German and Swedish medicines 
regulatory agencies to suspend the marketing authorisations for Octagam following such 
reports. The CHMP evaluation concluded thromboembolic events could be related to the 
presence of impurities which could act as clotting/coagulation factors in the product 
introduced during the manufacturing process and therefore recommended (i) a recall of 
all batches of Octagam and associated names and (ii) a suspension of its marketing 
authorisation(175). Later on, an in-depth review of all available data on the safety and 
quality issues concluded that the unexpected presence of a pro-coagulant, factor XIa, 
was the main cause of the thromboembolic events and that a number of critical steps in 
the manufacturing process could explain the presence of substances that triggered the 
thromboembolic events.  Given the number of corrective and preventive measures 
implemented by the MAH, including the requirement for performing post-marketing 
safety studies and the CHMP recommended lifting the suspension on April 2011. The 
same recommendations were then issued by the FDA on November 2011. Until this date, 
two more voluntary market withdrawals have taken place with different lots of Octagam 
in the US, in April 2016 and October 2017, with no associated reports of serious 
injury(177,178). 
GammaGard Liquid  
Certain lots of immune globulin intravenous (human) (GammaGard Liquid) were also 
withdrawn as a precautionary measure from the market in June 2010, following an 
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reports of an increased number of adverse event reports of allergic reactions associated 
with two lots of this product(174). GammaGard Liquid was approved in April 2005 and is 
indicated for the treatment of primary immunodeficiency disorders associated with 
defects in humoral immunity. No action was retrieved from the EU region. 
4.2.5 EMA 
Sitaxentan sodium was the only MA to be withdrawn from EU during the covering period 
for safety reasons. This medicinal product was approved for the treatment of patients 
with pulmonary arterial hypertension and had been known to be associated with liver 
toxicity. Since its initial marketing authorisation it had been contra-indicated in patients 
with mild to severe hepatic impairment and elevated aminotransferases prior to initiation 
of treatment. Voluntary worldwide market withdrawal was decided in December 2010, 
four years after its initial authorization in EU, given a new potentially life-threatening 
idiosyncratic risk of liver injury. At that time Thilen (sitaxentan sodium) was marketed in 
16 EU Member States, in Australia and in Canada(179). On the other hand, such product 
was never approved in the US, but not due to liver toxicity concerns. After the initial 
submission of the new drug application in 2005, the FDA issued a total of three complete 
response letters to the sponsor. Initial letters contained concerns and observations to be 
satisfied before approval, including a request for an additional clinical trial; while the third 
requested another study to demonstrate the drug’s effectiveness in exercise capacity. 
Ultimately, in 2007, US regulators did not grant approval for sitaxentan given their 
concern on a lack of efficacy as, although the data provided in the new drug application 
were suggestive of its effectiveness, the extent of improvement did not provide the 
substantial evidence of effectiveness needed for approval(83,180). 
Despite the prevalence of commercially and legally driven withdrawals in EU already 
described, 39.0% of such products had been either suspended (8.5%), recalled (14.6%) 
or recently assessed by an European Health Authority (15.8%). Results show that safety-
driven assessments were done for 20.3% of products later withdrawn for commercial or 
legal reasons, of which 33.3% (06) resulted in a recommendation to suspend the MA. A 
brief description of these cases is presented below. 
Laropiprant/ nicotinic acid 
On December 2012, the European Medicines Agency was made aware of the availability 
of preliminary results from a randomised clinical study (HPS2-THRIVE1) designed to 
assess the incremental benefit of nicotinic acid/laropiprant (as extended release 
formulation). Nicotinic acid/laropiprant, authorised in the EU as Tredaptive, Trevaclyn 
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and Pelzont since July 2008, was indicated for the treatment of dyslipidaemia. The 
preliminary results showed that no significant additional benefit in reducing the risk of 
major vascular events was found in taking laropiprant/ nicotinic acid together with a 
statin, compared with statin therapy alone. In addition, a higher frequency of non-fatal 
but serious side effects was seen in patients taking laropiprant/ nicotinic acid. A 
procedure under Article 20 was then initiated following which PRAC recommended the 
suspension of the marketing authorisations for nicotinic acid/laropiprant. To lift such 
suspension, the MAH would need to provide convincing data to identify a patient 
population in which the efficacy of nicotinic acid/laropiprant could demonstrated, and in 
which the benefit clearly outweighs the risks(181). The FDA on the other hand, had in 
fact issued a non-approval letter for nicotinic acid/laropiprant New Drug Application, 
requesting additional efficacy and safety data and suggesting the manufacturer to wait 
for the results of the HPS2-THRIVE cardiovascular outcomes study(182,183).  
Rosiglitazone-containing products 
On December 2010 the European Commission issued a decision for the suspension of 
the marketing authorization of rosiglitazone-containing medicines, following the 
availability of new studies questioning the cardiovascular safety of the medicine. Since 
its first authorisation in 2000, rosiglitazone had been recognised to be associated with 
fluid retention and increased risk of heart failure and its cardiovascular safety has always 
been kept under close review. Consequently, the use of rosiglitazone was restricted to a 
second-line treatment and contra-indicated in patients with heart failure or a history of 
heart failure. Further data from clinical trials, observational studies and meta-analyses of 
existing studies that became available since 2007 which suggested a possibly increased 
risk of ischaemic heart disease associated with the use of rosiglitazone and hence further 
restrictions on the use of these medicines in patients with ischaemic heart disease were 
introduced(184,185).  
EMA later considered that the availability of these recent studies had added to the 
knowledge about rosiglitazone and overall, the accumulated data supported an 
increased cardiovascular risk of rosiglitazone. The Agency considered that no further risk 
minimisation activities could be identified which would be expected to reduce the risks of 
rosiglitazone-containing products to an acceptable level or predict which patients may 
be at risk, taking into account the restrictions and warnings already in place. Having 
concluded that the risks associated with the use of rosiglitazone in the treatment of type 
2 diabetes mellitus outweigh its benefits, the marketing authorization was suspended. 
Such measures were to remain in place unless the marketing authorisation holder could 
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provide convincing data to identify a group of patients in whom the benefits of the 
medicines outweigh their risks. However the marketing authorizations for 
rosiglitazone/metformin and rosiglitazone expired on October 2013 and on July 2015, 
after the marketing authorization holder having failed to satisfy such requirements. 
Regarding rosiglitazone/glimepiride significant new data had not been submitted as part 
of the renewal application and the five-year marketing authorization also expired on June 
2011(185). 
On the other hand, the FDA issued on September 2010 and later on February 2011 a 
series of restrictions for prescribing and use of rosiglitazone-containing products. In 
addition to describing the cardiovascular risks, the drug labels were revised to state that 
rosiglitazone and rosiglitazone-containing medicines should only be used either in 
patients already being treated with these medicines, or in patients whose blood glucose 
levels could not be controlled with other anti-diabetic medicines and who, after consulting 
with their healthcare professional, do not wish to use pioglitazone-containing medicines. 
Additionally, as part of a REMS implemented in September 2010, healthcare providers 
and patients must enrol in a special program in order to prescribe and receive these 
drugs, the latter which would receive their medicine by mail order through specially 
certified pharmacies participating in the program(186). 
Developments in 2013 include the new re-evaluation of the Rosiglitazone Evaluated for 
Cardiovascular Outcomes and Regulation of Glycemia in Diabetes trial, based on which 
the FDA requested modifications to the rosiglitazone REMS program to remove the 
requirements for restricted distribution(187). 
4.2.6 Timing of regulatory action 
For all of products studied, the median time between approval and withdrawal dates was 
5.9 years (globally), with an average of 7 years for biological medicinal products and of 
5.4 years for small molecules. With regards to safety driven withdrawals and 
suspensions, the median time between approval and the regulatory action dates was 8.3 
years (globally), with an average of 4.5 years for biological medicinal products and an 
average of 9.1 years for small molecules. Additionally, 66.6% of the safety-related 
withdrawals were issued within 5 years after approval. 
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Figure 23 – Average time (years) between marketing authorization approval and withdrawal regardless of 
reason (A) for all products types (pink), for small molecules (blue) and for biologicals (green); and average 
time (years) between marketing authorization approval and safety driven withdrawal and/or suspension (B) 
for all products types (pink), for small molecules (blue) and for biologicals (green). 
 
4.3 Discussion 
Similarly to the results from DHPC analysis, data on withdrawals of marketing 
authorizations shows that such regulatory actions were pronominally taken for small 
molecules. Overall, the majority of the withdrawals occurred for commercial or legal 
reasons, with safety concerns being responsible for only 5.5% of the withdrawals. This 
figure is consistent with the 4.2% value obtained for safety market withdrawal of drugs 
approved in Canada between 1990 and 2009(188) and in line with European data from 
January 1999 to December 2009(87), although higher that the 2.9% reported for the 
United States between 1975 to 1999(98). The fact that no information was available from 
the FDA website on withdrawals for commercial reasons is a severe limitation for the 
overall comparison on global data. 
Despite the more frequent withdrawals for non-safety concerns, results show safety-
driven assessments in EU were done for 20.3% of products later withdrawn for 
commercial or legal reasons, of which 33.3% resulted in a recommendation to suspend 
the MA. This may suggest a higher frequency of emerging safety issues than the ones 
accounted for based on the public statement for withdrawal available at the EMA website. 
From all the withdrawn products, only one was removed from the marked by both the 
FDA and the EMA, due to lack of efficacy. Multiple cases were presented discussing 
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different regulatory actions for the same safety concerns for a particular product. Such 
results seem to highlight not only the considerable differences with regards to pre-
approval processes between the EU and the US, but also to reflect the distinct benefit-
risk balance assessment based on the regulatory powers available for both bodies and 
emphasis in risk communication/ implementing risk minimization activities, which have 
resulted in multiple well known for conflicting regulatory decisions throughout the years.  
Data from this analysis shows that majority of the withdrawals and suspensions for safety 
reasons was linked to Cardiac disorders (76.9%), which is consistent with previous 
findings for safety driven regulatory actions, particularly for small molecules(98,102,105) 
Overall, for small molecules, the average time taken until withdrawal was lower than the 
average time taken for all safety-related regulatory actions (i.e. withdrawals and 
suspensions), regardless of the reason for removal from the market. This is due to the 
high proportion of withdrawals for small molecule type drugs in the EU territory for pure 
commercial reasons within one year of granting of the marketing authorization.  
Average global figure of 8.3 years between approval and withdrawal for safety driven 
withdrawals and suspensions is higher than previous results(98,100,103) These findings 
can be explained partly by the long time lapse between approval and discontinuation of 
some products for the covering period (e.g. propoxyphene and sibutramine). 
Additionally, the different calculations used to determine time of action may also 
contribute, as previous publications determined time between approval date and date of 
first safety-driven regulatory action and or date of suspension, while this analysis 
calculated the time between medicinal product approval and withdrawal dates, even for 
products with previous safety findings or suspensions. Nonetheless, results also 
evidence that safety-related regulatory actions are mostly taken within the first 5 years 
after approval, which is in line with available literature. 
On the other hand, figures obtained for biologicals, suggest that earlier action is taken 
for such type of products when compared to small molecules, however sample size is 
too small for further considerations. 
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 Case study  
5.1 Valproic acid and related substances 
Valproic acid (2-propylpentanoic acid, N-dipropylacetic acid) is a branched short-chain 
fatty acid, derived from valeric acid, which was initially synthesized as an organic solvent. 
Its antiepileptic properties were recognized given its ability to protect experimental 
animals against seizures and its introduction for clinical use followed shortly after the 
publication of the first clinical study in 1964(189,190). The difference between valproate 
products (valproate sodium, divalproex sodium and valproic acid) is their solubility in 
water. As sodium valproate is very hygroscopic and in the gastrointestinal tract is 
impossible for it to disintegrate in equal form, without constant fluctuations, laboratories 
developed the sodium divalproate molecule(191). 
In Europe, valproate and related substances (valproic acid, sodium valproate, valproate 
semisodium, and valpromide) have been used since 1967 to treat epilepsy and since 
1995 to treat bipolar disorders. Nowadays, valproate is also indicated for the prophylaxis 
of migraine attacks in some of the EU Member states(192). In regards to the US territory, 
valproate products (valproate sodium, divalproex sodium and valproic acid) were initially 
granted market authorization in 1979 and are currently approved for the treatment of 
seizures, and manic or mixed episodes associated with bipolar disorder, and to prevent 
migraine headaches(193). However, the off-label use of valproate products for other 
psychiatric conditions, particularly as a mood stabilizer for patients with schizophrenia, 
appears to be prevelant(194–197). In fact, cumulatively until September 2017, a total of 
321 individual cases (1.21%), out of 26.570 cases reported cumulatively, had been 
identified in EudraVigilance for valproic acid and off-label use(198).  
Valproic acid (ATC code: N05AX) belongs to the pharmacotherapeutic group of 
psycholeptics; antipsychotics; other antipsychotics, and exerts its effects mainly on the 
central nervous system. Valproate’s exact mechanism of action is not fully understood, 
but it is thought to act through potentiation of the inhibitory action of gamma amino butyric 
acid, either by further synthesis or further metabolism of the neurotransmitter. Valproate 
may also work by suppressing repetitive neuronal firing through inhibition of voltage-
sensitive sodium channels, which has the effect of reducing excessive electrical activity 
in the brain(192,199–201). 
Valproate is generally regarded as one of the first-line treatments for most forms of 
symptomatic and idiopathic generalized epilepsies. In patients with newly diagnosed 
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partial seizures (with or without secondary generalization) and/or primarily generalized 
tonic-clonic seizures, the efficacy of valproate is comparable to that of phenytoin, 
carbamazepine and phenobarbital(199,202). 
As far as an overall safety profile with therapeutic use, the most common adverse effects 
are nausea, tremors, gastralgia, diarrhoea, extrapyramidal disorder, stupor, somnolence, 
convulsion, memory impairment, headache, nystagmus, confusional state, aggression, 
agitation, disturbance in attention, hyponatraemia, anaemia, thrombocytopenia, 
hypersensitivity, transient and/or dose related alopecia, dysmenorrhea, haemorrhage, 
deafness and weight increased(200). 
Additionally, like with other anti-epileptic medicines, use of valproate containing 
medicines in pregnant women increases the risk of birth defects in their children. 
Maternal use of valproic acid is however associated with a higher risk of certain birth 
defects than other anti-epileptic medicines. Data also suggests an association between 
in-utero exposure to valproate and the risk of developmental disorders (frequently 
associated with craniofacial abnormalities), particularly of verbal intelligence 
quotient(203). 
5.2 EU safety-related regulatory actions 
On April 2009, the Dutch national competent authority raised general concerns on the 
effectiveness and safety of valproic acid and valproate in regard to its use for acute 
treatment of manic episode and prevention of recurrence in patients with bipolar disorder. 
The Medicines Evaluation Board noted that there were differences among Member 
States in the marketing authorisations in this context and asked the CHMP to carry out 
a full assessment of the benefit-risk balance of valproic acid and valproate for this 
indication.  
The CHMP reviewed the information supplied by the companies that make valproate-
containing medicines to support the use of valproate-containing medicine in bipolar 
disorders, including published articles reporting the results of 16 clinical studies of 
valproate in acute mania (either in monotherapy or in combination) and in the prevention 
of recurrence of mood episodes in bipolar disorder. Following this review, PRAC 
recommended bipolar disorders indication was to be restricted to the treatment of manic 
episode when lithium is contraindicated or not tolerated. However, continuation of 
treatment after the manic episode can be considered in patients who have responded 
well to valproate. Furthermore updates to the product information were requested in 
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order to reflect the risks relating to the use during pregnancy, including the risk of birth 
defects and also the risk of developmental delay. At that point in time, the product 
information included warnings for valproic acid not to be used to treat epilepsy or bipolar 
disorders during pregnancy and in women of childbearing potential unless clearly 
necessary (e.g. in situations where other treatments are ineffective or not 
tolerated)(192,204). 
In the years following this review, several further studies were published, which allowed 
for a better understanding and characterisation of the risk of long term potential 
neurodevelopmental effects following in utero exposure to valproate. These publications 
suggested that in some children the effects appear to persist and manifest as a range of 
neurodevelopmental abnormalities and autism spectrum disorder. This new data also 
stated that the risk of neurodevelopmental delay and autism spectrum disorder may be 
independent of maternal confounders(203,205–207). Therefore, in October 2013, the 
UK’s National Competent Authority, the Medicines and Healthcare products Regulatory 
Agency (MHRA), triggered a referral under Article 31, requesting the PRAC to issue a 
recommendation on whether the balance of benefits and risks for these products was 
still positive in the approved indications, in female children, women of child bearing 
potential and pregnant women and whether the marketing authorisation for valproate 
and related substances should be maintained, varied, suspended or revoked. 
Additionally, the MHRA also argued that product information for valproic acid and related 
substances appeared to differ across EU Members and there was a need for further 
revisions in order to bring it in line with all the most current safety profile of the drug(208). 
A decision was reached by the European Agency in October 2014. Data from pre-clinical 
studies, pharmaco-epidemiological studies, published literature and spontaneous was 
assessed, the views of the relevant experts (e.g. in neurology, psychiatry, child 
neuropsychiatry, obstetrics etc.) on the safety and efficacy of valproate and related 
substances in female children, women of childbearing potential and pregnant women, 
the views of patients, families and carers and of healthcare professionals regarding the 
implications, the understanding and awareness of the risks associated with valproate in-
utero exposure were also considered. 
PRAC review confirmed that intra-uterine exposure to valproate and related substances 
is associated with (i) an increased risk of developmental disorders in the offspring and 
(ii) a known risk of congenital anomalies. Based on these conclusions the following 
safety-related regulatory actions were recommended(192): 
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I. Updates to the product information 
a. Valproate and related substances should not be used in female children, 
women of childbearing potential and pregnant women unless alternative 
treatments are ineffective or not tolerated in the following indications: 
treatment of primary generalised epileptic seizures, secondary 
generalised epileptic seizures and partial epileptic seizures; treatment of 
manic episode in bipolar disorder when lithium is contraindicated or not 
tolerated. The continuation of treatment after manic episode could be 
considered in patients who have responded to valproate for acute mania. 
b. Valproate and related substances should be contraindicated in 
prophylaxis of migraine attacks in pregnancy and women of childbearing 
potential who are not using effective methods of contraception during 
treatment with valproate. 
c. Further changes to the product information such as warnings and 
precautions and updated information on the risks related to exposure 
during pregnancy should be implemented to better inform the healthcare 
professionals and women. 
II. Updates to the conditions to the MAH to include the need to implement further 
risk minimisation measures (RMM) such as: 
a. Educational materials aimed to better inform patients and healthcare 
professionals on the risks, particularly targeting neurologists, 
psychiatrists, general practitioners, obstetricians/gynaecologists, family 
planning centres, pharmacists, health visitors, midwife, and school 
nurses. These include a guide for prescribers, a patient booklet, an 
acknowledgment of risk information form and a DHPC. 
b. A drug utilisation study to assess the effectiveness of the risk minimisation 
measures and to further characterise the prescribing patterns for 
valproate. The study design should aim to evaluate and quantify the 
effectiveness of the risk minimisation measures, and should include a pre- 
and post-implementation analysis and assessment. The study should 
also be conducted in more than one EU Member State. As a result of this 
new requirement the marketing-authorisation holders to carry out joint 
post-authorisation safety study, valproic acid and related substances 
were added to the list of medicines under additional monitoring includes 
medicines authorised in the European Union in January 2015(209). 
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On November 2014, Co-ordination Group for Mutual Recognition and Decentralised 
Procedures – Human (CMDh) endorsed above PRAC recommendations but several 
amendments were also made/included, namely a clarification about the population 
affected by the recommendations as these are also applicable to female adolescents 
(aged between 12 to 16-18 years) according to the ICH E11 age classification of the 
paediatric population; a clarification on the use of prolonged release formulation to avoid 
high peak plasma concentrations in the summary of product characteristics, and also a 
request for the first part of the package leaflet to be reviewed for clarity reasons(210).  
Based on these requirements, two observational studies were designed: 
- A Joint PASS Survey and Drug Utilisation Study among Health Care 
Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions 
of valproate in France, Germany, Spain, Sweden and United Kingdom 
(EUPAS11379), finalized on May 2017(211); 
- And A Joint Drug Utilisation Study (DUS) of valproate and related substances, in 
Europe, using databases, in order to describe the prescribing practices before 
and after the dissemination of risk minimisation measures (e.g. educational 
materials and Dear Healthcare Professional Communication) and to assess the 
effectiveness of these measures in females through measure of prevalence of 
prior medication used before valproate (still ongoing)(212). 
Besides the additional RMM implemented throughout EU territories, some countries 
have taken specific additional measures. For instance, in France a warning has been 
included on the outer packaging and additional DHPC circulated; a patient alert card and 
a pictogram on the outer packaging have been implemented more recently. French 
Health Authorities also published recommendations on how to replace valproate in 
female children, women of childbearing potential and pregnant women treated for 
epilepsy or bipolar disorder. The risk minimisation measures currently (November 2017) 
in place for valproic acid and related substances in the UK are presented in Table 6. 
Table 6 – Risk minimisation measures currently (November 2017) in place for valproic acid and related 
substances within the UK 
Educational Materials Brief description 
Checklist HCP – Risks in 
Female patients 
Checklist for prescribers related to Valproate use in 
female patients. 
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Educational Materials Brief description 
HCP Booklet – Risks in 
Female patients 
Healthcare professional risk minimisation booklet for 
Valproate in female patients (Annex IV - HCP Booklet – 
Risks in Female patients).  
Letter for Pharmacists – 
HCP - Risks in Female 
patients 
 
Communication letter to pharmacists explaining risk 
minimisation materials for managing patients taking 
Valproate based medicines 
Letter for Prescribers - 
Risks in Female patients 
Communication letter to specialists and specialist 
nurses/midwives managing patients treated with 
valproate‐based medicines (Annex V – Letter for 
Prescribers - Risks in Female patients) 
Letter for Primary Care HCP 
- Risks in Female patients 
 
Communication letter to HCP's providing primary care, 
obstetric or family planning services to female patients 
taking Valproate containing medicines. 
Letter for Specialists – 
Risks in Female patients 
Communication letter explaining risk minimisation 
materials for specialists managing patients taking 
Valproate based medicines. 
Patient Card – Risks in 
Female patients 
Risk minimization Patient card for Valproate in female 
patients. 
Patient Guide – Risks in 
Female patients 
Patient Guide risk minimisation booklet for Valproate in 
female patients. 
Valproate – Poster – 
Dispensary - Risks in 
Female patients 
Additional materials for pharmacists (Annex VI – Poster- 
Dispensary - Risks in Female patients). 
 
Safety Card - HCP - Risks in 
Female patients 
Additional materials for HCP's providing primary care, 
obstetric or family planning services. 
Shelf Barker - HCP - Risks 
in Female patients 
Additional materials for HCP's providing primary care, 
obstetric or family planning services. 
 
Similarly, since the EMA review in 2014, some EU member states have since carried out 
additional assessments of the impact of the measures at national level. In March 2017, 
French medicines regulator raised concerns about how effective the measures have 
been in increasing awareness and reducing valproate use appropriately in its various 
indications, and therefore asked EMA for a broad review on this topic(213). 
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EMA is currently examining the available evidence and consulting with relevant 
stakeholder groups. As a part of this new review of valproate use in pregnancy and 
women of childbearing age, the first ever public hearing was held by the Agency on 26 
September 2017 in order to learn more directly from the different views and experiences 
of people who have taken valproate and those caring for such people. 
On PRAC meeting of 5-8 February 2018, recommendations on new restrictions on use 
and a pregnancy prevention programme to be put in place have been made. Having 
examined the available evidence and consulted widely with healthcare professionals and 
with patients, including women and their children who have been affected by valproate 
use during pregnancy, through written submissions, expert meetings, meetings with 
stakeholders including healthcare professionals, patients’ organisations, patients and 
their families, and via a public hearing, the PRAC noted that women were still not always 
receiving the right information in a timely manner and that further measures were needed 
to help avoid use during pregnancy. However, it was also clear that for some women, 
such as those with particular forms of epilepsy, valproate is the only appropriate 
treatment and might be life-saving(214).  
Therefore, strengthening restrictions on the use of these products and introduction of 
new measures to require appropriate counselling and information for affected women 
have been proposed. Additionally, the MAHs of valproic acid and related substances 
have now been requested to carry out additional studies to further characterise the 
nature and extent of the risks posed by valproate and to monitor ongoing valproate use 
and the long-term effects from affected pregnancies(214). 
In March 2018 CMDh endorsed the implementation of new measures to strengthen 
previous restrictions on valproate use and the requirements to inform female patients of 
the risks of malformations and developmental problems from valproate exposure in 
pregnancy. The CMDh position will now be sent to the European Commission, which will 
take a final legally binding decision valid across the EU(215). 
5.3 US safety-related regulatory actions 
On January 2008, the FDA issued new information to health care professionals, the 
general public and MAHs in regard to the increased risk of suicidal thoughts and 
behaviours in patients taking antiepileptics, as a result of suicidality reports from placebo-
controlled studies for 11 antiepileptic drugs(216). Updates to the product label were 
requested for these products for Warnings and Information to Patients sections. 
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Additionally, the FDA also requested MAHs to submit a Risk Evaluation and Mitigation 
Strategy for each of these products. Medication Guide for patients was also to be 
implemented for several antiepileptics but not valproic acid. The latter constitutes of a 
handout developed by manufactures containing FDA-approved information about the 
risks of suicidal thoughts and behaviours associated with this class of drugs, which is to 
be distributed to patients, their families and caregivers when any of the referred 
antiepileptic products is dispensed(217,218). 
In December of the following year, the FDA published an Information for Health Care 
Professionals (also referred to as a Healthcare Professional Information sheet) on the 
risk of neural tube birth defects following prenatal exposure to valproate. HCP were also 
notified of other major birth defects associated to in-utero exposure of valproate 
products, such as craniofacial defects and cardiovascular malformations. Subsequent 
changes to the label were implemented to full address these safety concerns. 
Furthermore, HCP were requested to inform women of childbearing potential about these 
risks, and consider alternative therapies, especially if using valproate to treat migraines 
or other conditions not usually considered life-threatening. In fact, women of childbearing 
potential should only use valproate if it is essential to manage their medical condition. 
Those who are not actively planning a pregnancy should use effective contraception, as 
birth defect risks are particularly high during the first trimester, before many women know 
they are pregnant. In addition, FDA also required a patient Medication Guide for 
valproate at this instance(219).  
By 2011 other studies had been published concerning the safety profile of valproic acid 
and its use during pregnancy(220–223). Following the results of these epidemiologic 
studies the FDA issued a Drug Safety Communication informing the general public and 
HCPs that children born to mothers who take the anti-seizure medication valproate 
sodium, or related products, during pregnancy have an increased risk of lower cognitive 
test scores than children exposed to other anti-seizure medications during pregnancy. 
The long-term effects on cognitive development from exposure to valproate sodium or 
related products during pregnancy or whether these effects occur when fetal exposure 
is limited to less than the full duration of pregnancy, such as the first trimester, were 
however unknown at that point in time(224).  
US Health Authority requested therefore an update to the valproic acid and related 
products’ product information so that it could now capture the risk of lower cognitive test 
scores in the Warnings and Precautions section, the Use in Specific Populations: 
Pregnancy section. Medication Guides were also to be developed for this safety issue 
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and a drug safety podcast was released for HCPs(224,225). Current version of 
Medication Guide is present in Annex VII – Depakote US Medication guide. 
Furthermore in 2013, the FDA made yet another safety announcement advising health 
care professionals and women in regard to the safety profile of valproate sodium and 
related substances, given the information from a recent study, suggesting a decrease in 
IQ scores in children whose mothers took them while pregnant. Label updates were once 
again recommended: valproate sodium and related products were now to be 
contraindicated and should not be taken by pregnant women for the prevention of 
migraine headaches and stronger warnings about use during pregnancy will also be 
included. Moreover, valproate’s pregnancy category for migraine use was changed from 
"D" (the potential benefit of the drug in pregnant women may be acceptable despite its 
potential risks) to "X" (the risk of use in pregnant women clearly outweighs any possible 
benefit of the drug)(226). 
On the other hand, for valproate use in pregnant women with epilepsy or bipolar disorder, 
FDA recommended that valproate products should only be prescribed if other 
medications are not effective in treating the condition or are otherwise unacceptable. 
Valproate products will remain in pregnancy category D for treating epilepsy and manic 
episodes associated with bipolar disorder. With regard to women of childbearing age 
who are not pregnant, warnings were to be implemented for valproate not be taken for 
any condition unless the drug is considered essential to the management of the woman's 
medical condition. All non-pregnant women of childbearing age taking valproate products 
should also use effective birth control(226). 
5.4 Quick comparison 
Valproic acid and related substances have been approved and marketed for 38 to 50 
years in US and EU markets respectively. From the review of literature article and 
published studies, both regulatory agencies have identified the same safety concerns in 
regard to the teratogenicity and the use of valproic acid and related products in children, 
women of childbearing potential and during pregnancy, particularly given the increased 
risk of congenital malformations, major structural abnormalities and serious 
neurodevelopmental effects. Over the years, these competent authorities have also 
taken several actions to inform both the healthcare practitioners and the general public 
of such safety issues, but also to address and mitigate these risks. In fact, updates on 
these risks were widely notified by the US medicines health authority in its website and 
through safety communications to the general public and even podcasts for the HCP. On 
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the other hand, the EMA website also includes a record of all final documents for each 
of the stages of the referrals and comprehensive transparency on the scientific rational 
for the safety regulatory actions taken. As a matter of fact, such regulatory actions 
include multiple updates to the product information and additional measures, common to 
both territories. The FDA requested manufactures to include a black box warning for fetal 
risk and a medication guide describing the risks of valproate for patients; while the EMA 
required MAHs to develop educational materials aimed to for HCPs (namely a guide for 
prescribers, a patient booklet, an acknowledgment of risk information form and a DHPC) 
as well as a drug utilisation study to assess the effectiveness of the risk minimisation 
measures and to further characterise the prescribing patterns for valproate. 
Recent developments in regard to the to the use of valproate and related substances 
during pregnancy and in women of childbearing potential with no effective contraception 
in the treatment of manic episodes of bipolar disorder and on the need of additional RMM 
following the review of the effectiveness of the implemented RMM across all indications 
are being only discussed in the EU territory at this point in time. 
A website is also available in the US territory providing patients and HCPs with some 
tools and information to learn more about valproic acid and its prescribing information, 
as well as further guidance on epilepsy and bipolar mania and its management. The 
medication guide can also be retrieved from here. 
The distinct set of regulatory actions taken and attention given to valproate use in 
pregnancy and women of childbearing age can be justified not only by the structurally 
different pharmacovigilance mechanisms implemented, instruments available to 
regulators in each territory and post-marketing requirements, but also given the decision-
making approaches of both organizations. Inconsistencies in both structure and content 
of the labelling information between EU and US territories and to some extent within in 
EU territories, given the approved indication for the treatment of migraines should be 
noted. Furthermore, one should take into consideration the fact that, in all of the safety 
reviews conducted for EU territory, the notification trigger has originated from a distinct 
a national competent authority, which could hint on the diversity of prioritization and 
analysis of new safety information for each of the member states, which only occurs in a 
plural union of states as the EU. No data was available in regard to overall patient 
exposure or prescription practices in both territories to allow further characterization or 
comparison.  
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 Limitations 
This analysis presents some important limitations, particularly the fact that all the 
information was retrieved from the public domain, including health authority websites 
which may not capture the entire set of information necessary. This is the clear case of 
US DHPC for which there is no current database of retrieval. Additionally, DHPC in the 
EU space were considered only for Portugal and the UK and do not account for any other 
safety communication which could have been distributed for other countries. Similarly, 
US withdrawals for commercial reasons were not available in the FDA website.  
Another limitation is that only safety issues linked to DHPC and drug withdrawals and/or 
suspensions were fully evaluated. Other forms of safety-related actions, such as 
changes in the drug labelling, including additions and changes to the US BBW, or 
requests for post-authorisation safety studies were not analysed. 
Additionally, for further characterizing medicinal products with regards to their safety-
related regulatory actions, it would also have been interesting to consider the 
assessment history, for instance through the study of the PSUR submission frequency, 
as well as the conditions of the MA, including whether such medicinal products belong 
to the list of medicines under additional monitoring. 
Finally, the exact date a medicinal product is launched on the market is not available in 
the public domain and hence the presented results may overestimate elapsed time 
between widespread prescribing of a drug and the emergence of major safety concerns 
and subsequent safety-driven regulatory actions. 
 Conclusion 
The incomplete safety profile of new medicinal products and the limited knowledge 
available on the benefit-risk profile of a drug at the time of granting a marketing 
authorisation is a well-established fact. The natural history of approved drugs 
comprehends the discovery of new and important safety information in the post-
marketing setting and hence its timely identification and the response to drug-related 
risks is a crucial part of the mission of pharmacovigilance, health authorities and 
pharmaceutical companies. 
Over the years, multiple studies have analysed safety-related regulatory actions, mostly 
for particular settings, such as for specific drug groups (e.g. biologicals, orphan 
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medicines and exceptional circumstances/ conditional (accelerated) approval 
procedures) or individual countries.  
However, the lack of an overall recent picture of safety-driven regulatory actions for 
medicinal products, both small molecules and biologics, and the significant implications 
for pharmacovigilance activities following the new legal frameworks in 2007 (for the US) 
and in 2012 (for the EU) were the triggers of this study. The proposed analysis of the 
safety-driven regulatory actions between 2010 and 2015, in either of these two territories, 
aimed to better characterise and compare recommendations provided by the EMA and 
FDA, to assess the apparent lack of harmony in addressing specific safety issues, and 
to present a specific scenario depictive of the comparison exercise.  
On that regard, a comprehensive description of the history, organizational structure, 
processes and objectives of two of the major regulatory authorities was performed. 
Substantial differences between FDA and EMA pertaining to pharmacovigilance 
activities and safety-driven regulatory actions were illustrated. Simultaneously, 
similarities in terms of aims, responsibilities and objectives, and important collaborative 
initiatives between these two regions were also described. 
The results obtained indicate DHPC are more frequently distributed in the EU than the 
US. However, the majority of the safety risks associated to marketed products in the US 
territory had been divulged to HCP and the general public by other risk communication 
tools available to the FDA. There was a prevalence of both safety driven DHPC and 
withdrawals for small molecules and data retrieved supports previous findings that 
differences have been shown to exist in the nature of the safety-related regulatory 
actions for biologicals compared with small molecules. For the latter, cardiac disorders 
related AE appear as a leading trigger for safety-driven regulatory actions and data 
suggests more efforts still need to be allocated for tackling medication error-related 
adverse events. Spontaneous reports continues to account for the majority of the source 
data for triggering safety driven DHPC in all regions, but findings for clinical trials and 
epidemiological studies supports the observed increment use these sources in 
identifying and evaluating safety issues. With regards to timing of regulatory action, 
66.6% of the safety-related withdrawals were issued within 5 years after approval, while 
50.4% of the safety driven DHPC were issued within 6 years after approval.  
The use of valproic acid in children, women of childbearing potential and potential and 
during pregnancy given the associated risks of congenital malformations, major 
structural abnormalities and serious neurodevelopmental effects was chosen as case 
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study. The distinct set of regulatory actions taken can be justified not only by the 
structurally different pharmacovigilance mechanisms implemented and instruments 
available to regulators in each territory but also given the inconsistencies in both 
structure and content of the labelling information between EU and US territories and to 
some extent within in EU territories. 
Overall, all of the above comparison exercises allowed for the discussion on legislative 
framework and processes of the FDA and the EMA, which if analysed can help improve 
public awareness and may allow for a better insight and understanding on matters of 
divergent drug approvals and post-marketing safety recommendations, either it being 
signal management activities, label updates, additional risk minimization measures and 
withdrawals/suspensions.  
Moreover, the dynamic nature of regulatory processes for pharmaceutical risk 
management is still present on today’s exciting pharmacovigilance landscape and future 
regulatory standardization and increased collaboration may still be necessary to further 
help in reducing redundancy and support the review/assessment processes for the 
benefit of regulators, pharmaceutical industries and the patients. 
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Novartis Pharmaceuticals Corporation 
East Hanover, New Jersey 
September 13, 2010 
 
 
 
 
 
 
Dear Healthcare Professional Communication regarding medication errors associated 
with the use of Exelon
®
 Patch (rivastigmine transdermal system). 
EXELON
®
 PATCH (rivastigmine transdermal system) is indicated for the treatment of mild 
to moderate dementia of the Alzheimer’s type and mild to moderate dementia associated with 
Parkinson’s disease. 
Dear Colleague,  
Novartis Pharmaceuticals Corporation, in agreement with the Food and Drug Administration, 
would like to remind Healthcare Professionals of the importance of the proper use and 
application of Exelon
®
 Patch (rivastigmine transdermal system) and the need to instruct 
patients and caregivers on correct application techniques for the use of Exelon Patch. 
Key messages 
 Medication errors with Exelon patches have resulted in serious adverse events; some cases 
have required hospitalization, and rarely, led to death.  
 The majority of medication errors have involved not removing the old patch prior to 
applying a new one and the application of multiple patches at one time. 
 It is important for healthcare professionals to instruct patients and caregivers on 
the proper use of the transdermal patch and particularly that: 
o only one transdermal patch should be applied per day to healthy skin on 
only one of the recommended locations: the upper or lower back, or upper 
arm or chest; 
o the patch should be replaced by a new one after 24 hours, and the 
previous day’s patch must be removed before applying a new patch to a 
different skin location; 
o to help minimize skin irritation, application to the same skin location 
within 14 days should be avoided; and 
o the transdermal patch should not be cut into pieces. 
IMPORTANT  
DRUG 
WARNING 
 2  
 
Further information on medication errors  
Novartis has received post-marketing reports of medication errors associated with the use of 
Exelon
®
 Patch.  The most common types of medication errors reported were drug 
administration error, wrong technique in drug usage process, and incorrect dose administered.  
The most frequently reported medication errors involve not removing the old patch prior to 
applying a new one and application of more than one patch at the same time. Other common 
errors are application on non-recommended sites or on the same area for several weeks, 
cutting the patch into several pieces, and dosing errors during prescribing or dispensing.  
Healthcare professionals, caregivers, or the patients themselves have been involved in these 
errors.  
Overdose with rivastigmine has been reported.  The typical symptoms reported in association 
with overdose include nausea, vomiting, diarrhea, hypertension, and hallucinations.  
Bradycardia or syncope that may be associated with malaise or falls, has also occurred.  
Serious medical outcomes, including death, may occur if medication errors involving Exelon
®
 
Patch are not corrected in a timely manner and properly managed.  In case of overdose, all 
Exelon
®
 patches should be immediately removed and no further patch should be applied for 
the next 24 hours.  Please refer to section 10 Overdosage in the attached insert labeling for 
additional details concerning the proper management of overdose related to Exelon
®
 Patch. 
Further information and recommendations to healthcare professionals 
Healthcare professionals should be well informed on the proper use and administration of 
Exelon
®
 Patch as described in the attached insert labeling.  Patients and caregivers must 
follow the instructions on “HOW TO USE EXELON” as described in the attached FDA-
Approved Patient Labeling.  Physicians should advise patients and caregivers accordingly 
prior to initiating therapy with Exelon
®
 Patch.  
Important Safety Information 
Exelon Patch is contraindicated in patients with known hypersensitivity to rivastigmine, other 
carbamate derivatives, or other components of the formulation. 
Medication errors with Exelon Patch have resulted in serious adverse events; some cases have 
required hospitalization, and rarely, led to death. The majority of medication errors have 
involved not removing the old patch when putting on a new one and the use of multiple 
patches at one time.  Only one Exelon Patch should be worn at a time. 
At higher-than-recommended doses, Exelon Patch use is associated with significant 
gastrointestinal adverse reactions, including nausea, vomiting, diarrhea, 
anorexia/decreased appetite, and weight loss.  For this reason, patients administered 
Exelon Patch should always be started at a dose of 4.6 mg/24 hours and titrated to the 
maintenance dose of 9.5 mg/24 hours. If treatment with Exelon Patch is interrupted for 
longer than three days, treatment should be reinitiated with the lowest daily dose to 
reduce the possibility of severe vomiting and its potentially serious sequelae.  It is critical 
to inform patients and caregivers that if therapy has been interrupted for more than 
three days, the next dose should not be administered until they have discussed this with 
the physician. 
In a clinical trial, the most commonly observed adverse reactions with Exelon Patch occurring 
at a frequency of at least 5% and greater than placebo with administration of 9.5 mg/24 hours 
 3  
 
were nausea, vomiting, and diarrhea (7%, 6%, 6% for Exelon Patch 9.5 mg/24 hours versus 
5%, 3%, 3% for placebo, respectively).   
Weight should be monitored during therapy with Exelon Patch.  Weight loss (≥7% of baseline 
weight) occurred in 3% of subjects receiving the 9.5 mg/24 hours dose of Exelon Patch in 
clinical trials.  Patients with body weight below 50 KG may experience more adverse events 
and may be more likely to discontinue Exelon Patch due to adverse events.   
In view of its pharmacodynamic effects, rivastigmine should not be given concomitantly with 
other cholinomimetic drugs.  Rivastigmine might interfere with the activity of anticholinergic 
medications.  
Due to increased cholinergic activity, cholinesterase inhibitors may increase gastric acid 
secretion and/or have vagotonic effects on heart rate.  Caution is recommended in patients 
with sick sinus syndrome, conduction defects, gastroduodenal ulcerative conditions (including 
those predisposed by concomitant medications), gastrointestinal bleeding, asthma or chronic 
obstructive pulmonary disease, urinary obstruction, and seizures. 
Call for reporting 
Healthcare professionals should report any suspected adverse reactions associated with the 
use of Exelon to the Food and Drug Administration at 1-800-FDA-1088 or 
www.fda.gov/medwatch .  
Communication information 
Should you have any questions or require additional information regarding the use of Exelon 
(rivastigmine), please contact Novartis Pharmaceuticals Corporation at 1-888-669-6682. 
 
 
Todd Gruber, MD 
Executive Director, Pharmacovigilance 
Drug Safety & Epidemiology 
 
Darlene Jody, MD 
Head, Medical & Scientific Affairs 
Specialty Medicines 
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Annex IV - HCP Booklet – Risks in Female patients 
  
This booklet was last updated in 
January 2016
This booklet must be read before considering 
prescribing valproate. It is provided as part of 
the risk minimization measures developed to 
inform prescribers of the risks associated with 
the use of valproate by females of childbearing 
potential and during pregnancy.   
Important Information 
for Healthcare 
Professionals on the 
Risks of Valproate 
 in Female Patients
 This medicinal product is subject to additional monitoring. 
2
3 
This booklet provides up-to-date information about the risk of 
neurodevelopmental disorders in children of women who have 
taken valproate during pregnancy in addition to the known risk of 
congenital malformations in exposed babies.  
This booklet should be used in conjunction with the Patient 
Guide. To learn more about valproate, please read the complete 
Summary of Product Characteristics before prescribing valproate.
Adverse event reporting
Adverse events should be reported. Reporting forms and information can 
be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to the Sanofi drug safety 
department on 01483 554242, or to the relevant manufacturer of the 
product if not Sanofi.
!
4What you should know about the risks 
of valproic acid use in female patients 
VALPROATE contains valproic acid, an active ingredient with known teratogenic 
effects which may result in congenital malformations. Available data also show 
that in utero exposure to valproate can be associated with an increased risk of 
developmental disorders. These risks are briefly described below.  
1. Congenital malformations 
Data derived from a meta-analysis (including registries and cohort studies) has 
shown that 10.73% of children of women with epilepsy exposed to valproate 
monotherapy during pregnancy suffer from congenital malformations (95% CI: 
8.16 -13.29), which represents a greater risk of major malformations than for 
the general population, for whom the risk is equal to about 2-3%1. Available data 
show the risk is dose dependent. The risk is greatest at higher doses (above 1g 
daily). A threshold dose below which no risk exists cannot be established based on 
available data. 
The most common types of malformations include neural tube defects, facial 
dysmorphism, cleft lip and palate, craniostenosis, cardiac, renal and urogenital 
defects, limb defects (including bilateral aplasia of the radius), and multiple 
anomalies involving various body systems.  
2. Developmental disorders 
Exposure to valproate in utero can have adverse effects on mental and physical 
development of the exposed children. The risk seems to be dose-dependent but 
a threshold dose below which no risk exists, cannot be established based on 
available data. The exact gestational period of risk for these effects is uncertain 
and the possibility of a risk throughout the entire pregnancy cannot be excluded.  
Studies2–5 in preschool children exposed in utero to valproate show that up to 
30-40% experience delays in their early development such as talking and walking 
later, lower intellectual abilities, poor language skills (speaking and understanding) 
and memory problems.  
5Intelligence quotient (IQ) measured in school aged children (age 6) with a history 
of valproate exposure in utero was on average 7-10 points lower than those 
children exposed to other antiepileptic drugs6. Although the role of confounding 
cannot be excluded, there is evidence in children exposed to valproate that the risk 
of intellectual impairment may be independent from maternal IQ. 
There are limited data on the long-term outcomes. 
Available data show that children exposed to valproate in utero are at increased 
risk of autistic spectrum disorder (approximately three-fold) and childhood autism 
(approximately five-fold) compared with the general study population7. 
Limited data suggests that children exposed to valproate in utero may be more 
likely to develop symptoms of attention deficit/hyperactivity disorder (ADHD)8.
6Treatment of female patients with 
valproate
A. Female child first prescription
After medical evaluation, if you are considering prescribing valproate to your patient: 
 ✓ Confirm that treatment with valproate is appropriate for your patient (i.e. 
alternative treatments are ineffective or not tolerated). 
 ✓ Discuss the following topics with your patient and relevant family members/
care-givers: 
• Risks to pregnancy that are associated with the underlying condition; 
• Risks related to treatment, including risks related to valproate when used in 
pregnancy;  
• Need for an effective contraception method to avoid unplanned pregnancy; 
• Need for regular review of treatment. 
 ✓ Assess the most appropriate timing to provide advice on effective contraception 
methods and refer your patient to a specialist if needed. 
 ✓ Ensure that your patient/family members/caregivers of the patient have 
understood the potential consequences when used in pregnancy and has/have 
an adequate level of understanding of the risks.  
 ✓ Give a copy of the Patient Guide to your patient 
 ✓ Complete the checklist with your patient and keep a copy in the patient’s 
medical records. 
 ✓ Advise your patient to contact you immediately if she thinks she might be 
pregnant or becomes pregnant. 
 ✓ Plan to review the need for treatment when she is able to become pregnant.
7B.  Woman of childbearing age who is not 
planning pregnancy 
After medical evaluation, you are considering prescribing valproate to your patient: 
 ✓ Confirm that treatment with valproate is appropriate for your patient (i.e. 
alternative treatments are ineffective or not tolerated). 
 ✓ Discuss the following topics with your patient: 
• Risks to pregnancy that are associated with the underlying condition; 
• Risks related to treatment, including risks related to valproate when used 
in pregnancy; 
• Need for an effective contraception method to avoid unplanned pregnancy; 
• Need for regular review of treatment.
 ✓ Assess the relevance of preconception counselling. 
 ✓ Ensure that your patient has understood the potential risks to the child of using 
valproate during pregnancy and has an adequate level of understanding of the 
risks, and that she understands the importance of using contraception to avoid 
unplanned pregnancy. 
 ✓ Give a copy of the Patient Guide to your patient.
 ✓ Complete the checklist with your patient and keep a copy in the patient’s 
medical records. 
 ✓ Advise your patient to contact you:
• if she thinks she might be pregnant or becomes pregnant; 
• in case of any adverse events associated with her treatment.
8C. Woman of childbearing age who is planning pregnancy 
 ✓ Remind your patients of teratogenic risks and risks of developmental disorders 
that can be seriously debilitating when taking valproate during pregnancy but 
also the risks of untreated seizures or bipolar disorder. 
 ✓ Reassess the benefit/risk of valproate therapy, whatever the indication: 
• Consider if stopping treatment or switching to an alternative is appropriate. 
• If, further to a careful evaluation of the risks and benefits, valproate 
treatment is to be continued:
 ✓ It is recommended to divide the daily dose into several small doses to be 
taken throughout the day at the lowest effective dosage possible. 
 ✓ The use of a prolonged-release formulation may be preferable to other 
treatment forms. 
There is no dose threshold considered to be without any risk but the risk of 
birth defects and developmental disorders is higher at greater doses.
• Both valproate monotherapy and valproate polytherapy are associated 
with congenital malformations. Available data suggest that antiepileptic 
polytherapy including valproate is associated with a greater risk of abnormal 
pregnancy outcome than valproate monotherapy. 
• Folic acid supplementation may decrease the general risk of neural tube 
defects but there is some evidence that it does not reduce the risk of birth 
defects associated with in utero valproate exposure. 
 ✓ Refer your patient to specialists for preconception advice. 
 ✓ Ensure that your patient has understood the potential risks to the pregnancy, 
and has an adequate level of understanding of the risks.
 ✓ Give a copy of the Patient Guide to your patient.
 ✓ Complete the checklist with your patient and keep a copy in the patient’s 
medical records. 
 ✓ Advise your patient to contact their family doctor and specialist as soon as 
she thinks she might be pregnant or becomes pregnant in order to initiate 
appropriate pregnancy monitoring, including prenatal monitoring to detect the 
possible occurrence of neural tube defects or other malformations. 
9D. Woman with unplanned pregnancy
 ✓ Schedule an urgent consultation with your patient to review treatment as soon 
as possible to reconsider the benefits and risks of valproate. 
 ✓ Explain why she should continue with her treatment until you have seen her, 
unless you are able to give other advice based on your assessment of the 
situation. 
• If, further to a careful evaluation of the risks and benefits, valproate 
treatment is to be continued:
 ✓  It is recommended to divide the daily dose into several small doses to be 
taken throughout the day at the lowest effective dosage possible. 
 ✓ The use of a prolonged-release formulation may be preferable to other 
treatment forms. 
• Both valproate monotherapy and valproate polytherapy are associated 
with congenital malformations. Available data suggest that antiepileptic 
polytherapy including valproate is associated with a greater risk of abnormal 
pregnancy outcome than valproate monotherapy. 
 ✓ Ensure that your patient: 
• has fully understood the risks related to valproate and consider further counselling. 
• has received the Patient Guide. 
 ✓ Complete the checklist with your patient and keep a copy in the patient’s 
medical records. This record is the opportunity to assess whether the patient has 
fully understood the risks. 
 ✓ Initiate specialized prenatal monitoring in order to detect the possible 
occurrence of neural tube defects or other malformations.
10
Summary
A. Female child first prescription 
1. Explain potential risks of the disease itself as well as the future risks for the 
unborn child and the risks associated with use of valproate in pregnancy 
2. Assess your patient’s need for treatment with valproate 
3. Inform your patient about the need to use effective contraception as soon as it 
is relevant 
4. Ensure that your patient has received the Patient Guide 
5. Where applicable, advise your patient to contact you immediately if she thinks 
she might be pregnant or becomes pregnant. 
B. Woman of childbearing age who is not planning 
pregnancy 
1. Explain potential risks of treatment and of untreated disease for the unborn 
child 
2. Assess your patient’s need for treatment with valproate 
3. Inform your patient about the need to use effective contraception 
4. Ensure that your patient has received the Patient Guide 
5. Advise your patient to contact you immediately if she thinks she might be 
pregnant or becomes pregnant.  
C. Woman of childbearing age who is planning pregnancy 
1. Explain potential risks of the disease itself on the unborn child, independent 
from valproate’s own risks. 
2. Reassess benefit/risk of patient’s therapy 
3. Adapt current treatment 
4. Advise your patient to contact you if she thinks she might be pregnant or 
becomes pregnant
5. Ensure that your patient has received the Patient Guide. 
11
D. Woman with unplanned pregnancy 
1. Inform her to keep taking her treatment until you have seen her 
2. Schedule an urgent consultation 
3. Re-assess the benefit/risk of her therapy 
4. Ensure that your patient has understood the risks related to valproate and 
consider counselling 
5. Ensure that your patient has received the Patient Guide. 
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July 2017 
 
SAGB.VPA.15.12.1440f (1)                                                                                                July 2017  
 
Important Safety Information – Action needed – Please Read 
Valproate medicines: only for use when no other treatment is effective or 
tolerated in girls, women of childbearing age, and women who are pregnant 
or planning pregnancy; important actions required 
 
This letter is for specialists and specialist nurses/midwives managing patients treated with 
valproate‐based medicines (sodium valproate [Epilim▼, Episenta▼]; valproic acid, 
sodium valproate [Epilim▼]; valproate semisodium [Depakote▼]), and general 
practitioners who provide primary care to these patients.  
 
 
Dear Healthcare Professional 
 
This letter is sent in follow‐up to the communication issued by the Medicines and 
Healthcare products Regulatory Agency in January 2015, and a further mailing on behalf of 
all valproate manufacturers in February 2016. It supplements the Patient Safety Alert on 
valproate issued by the MHRA and NHS Improvement on 6 April 2017 and those 
subsequently sent in Scotland, Wales and Northern Ireland.  Previous communications 
advised that valproate should only be used in girls, women of child bearing age and those 
who are pregnant or planning pregnancy when no other treatment is effective or 
tolerated. This is because children exposed in utero to valproate are at a high risk of 
serious developmental disorders (in up to 30–40% of cases) and/or congenital 
malformations (in approximately 10% of cases).  
 
Despite these communications, valproate continues to be used frequently in this patient 
group.  A recent survey of women of childbearing age taking valproate for epilepsy has 
identified that 20% had not been informed of these risks and 80% had not received any 
written information from their HCPs. Prescribing data show little change in the rate of 
prescription of valproate to girls and women of childbearing age since 2015, regardless of 
the indication. A significant number of patients remain at risk of inadvertent exposure to 
valproate in pregnancy and further efforts and actions are needed from prescribers and 
dispensers of valproate to reduce the risks that this entails. 
 
Please turn over to see the actions that you are being asked to perform.   
July 2017 
 
SAGB.VPA.15.12.1440f (1)                                                                                                July 2017  
 
THE RISK: Children exposed in utero to valproate are at a high risk of serious 
developmental disorders (in up to 30–40% of cases) and/or congenital malformations (in 
approximately 10% of cases). 
 
For this reason, you are asked to take the following actions: 
 
 DO NOT prescribe valproate to female children, female adolescents, women of 
childbearing potential, or pregnant women UNLESS other treatments are not effective 
or other treatments are not tolerated. 
 
 ONLY doctors experienced in managing epilepsy or bipolar disorder should prescribe 
valproate to these patients, and must supervise ongoing treatment with a review 
annually, at a minimum. 
 
 If you prescribe valproate YOU MUST INFORM all girls and women of childbearing age 
of the following, and ensure the information is understood: 
1. the risks to a baby from taking valproate during pregnancy; 
2. the need to use effective contraception while taking valproate; 
3. the need for regular (at least annual) review of treatment; 
4. the need to rapidly consult you if planning a pregnancy or becomes pregnant 
 
 If you are a General Practitioner caring for girls or women of childbearing age taking 
valproate, YOU MUST ENSURE that your patient is seen by the specialist responsible 
for prescribing valproate at least annually, and as a matter of urgency if she is planning 
pregnancy or becomes pregnant. 
 
To support effective prescribing practice, the enclosed booklet “Important Information for 
Healthcare Professionals on the Risks of Valproate in Female Patients” provides information 
on the risks and actions you are required to take. 
 
Also enclosed is an information booklet to provide to patients: “Valproate Patient Guide”. 
This is intended to be distributed by specialists initiating and supervising treatment with 
valproate, and you should give a copy to every girl or woman of childbearing age taking 
valproate. In addition, General Practitioners and Pharmacists are encouraged to provide 
copies to these patients who are not already aware of the information, alongside a reminder 
card provided by pharmacists when valproate is dispended. 
 
Additional copies of both booklets can be ordered, at no cost, by contacting Sanofi Medical 
Information on 0845 372 7101 or by emailing UK‐medicalinformation@sanofi.com. They can 
also be downloaded from the EMC website (www.medicines.org.uk) where they will be 
found linked with entries for medicines containing valproate.  
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Finally, a checklist has been developed to use during patient consultations. This will help 
ensure that the key points regarding the risks of valproate are discussed with the patient, 
and then when valproate is prescribed it is not being used inappropriately. This should be 
used with every girl and women of childbearing age when valproate is FIRST PRESCRIBED 
and at EVERY subsequent review, at least annually. 
 
The checklist is printed at the end of this letter, and additional copies can be downloaded 
from the EMC website (www.medicines.org.uk) where they will be found linked with entries 
for medicines containing valproate. 
 
You may find it helpful to keep this letter, and refer especially to pages 2 and 4 when 
initiating or reviewing valproate in girls and women of childbearing age. It may be helpful to 
display these two pages as a ready reference for relevant prescribers. 
 
Call for reporting: 
All valproate‐containing drugs are subject to additional monitoring. Any suspected adverse 
events should be reported. Reporting forms and information can be found at 
www.mhra.gov.uk/yellowcard. Adverse events should also be reported to the 
pharmaceutical company proving the valproate preparation, contactable at the address 
indicated on the packaging, in the Summary of Product Characteristics or Patient Leaflet, or 
in the BNF. 
 
Thank you for your co‐operation in following these requirements. This will help ensure 
appropriate use of valproate in this patient group and minimise these significant risks. 
 
Yours faithfully 
 
 
Dr Andrew Hockey FFPM 
Consultant in Pharmaceutical Medicine, and 
Medical Head – General Medicines, Sanofi UK 
 
This letter is sent at the request and with the approval of the Medicines and Healthcare 
products Regulatory Agency. 
 
July 2017 
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Treatment with valproate for female patients: Checklist for 
patients and prescribers 
 
A. Checklist for Prescribers 
 
Name of Patient /carer 
 
I confirm that the above named patient does not respond adequately or tolerate other  
treatments or medical treatments and requires valproate 
 
I have discussed with the above named Patient/carer: 
 
The overall risks of an approximately 10% chance of birth defects and up to  
30–40% chance of a wide range of early developmental problems that can lead  
to significant learning difficulties in children exposed to treatment with  
valproate during pregnancy.  
 
Individual risk can be minimised by use of the lowest possible effective dose 
 
The need for contraception (if child bearing age) 
 
The need for regular review of the need for treatment 
  
The need for urgent review if the patient is planning a pregnancy  
 
I have given the patient/carer a copy of the patient information booklet  
 
 
Name of Prescriber       Date   
  
 
 
 
B. Patient /Carer Checklist 
 
I understand: 
 
Why treatment with valproate rather than another medicine is considered 
necessary for me  
 
The risks of an approximately 10% chance of birth defects and up to 30–40% chance  
of a wide range of early developmental problems that can lead to significant learning  
difficulties in children exposed to treatment with valproate during pregnancy.  
 
That I am advised to use contraception if not planning a pregnancy 
 
That my treatment should be reviewed regularly 
 
That I should request an urgent review if planning a pregnancy PRIOR  
to attempting to conceive 
 
 
 
Name of Patient/ Carer     Date 
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Annex VI – Poster- Dispensary - Risks in Female patients 
  
 WARNING FOR 
WOMEN AND GIRLS
ACTION FOR THE PHARMACIST/PHARMACY STAFF
3 When dispensing any valproate preparation to female children, female 
adolescents, women of childbearing potential or pregnant women 
CHECK that their prescriber has discussed the risks of in utero exposure 
with them and they are aware of these.
3 If the prescriber HAS NOT DISCUSSED the risk with the patient, contact 
the prescriber and remind them of their responsibility to do so and ask 
them to arrange an urgent follow-up appointment with the patient.
3 PROVIDE a Valproate Patient Card every time you dispense a valproate 
preparation to female children, female adolescents, and women of 
childbearing potential or pregnant woman.
3 ASK if they have received a Valproate Patient Guide (booklet), and  
if not provide a copy.
3 ADVISE to always use contraception and to see their prescriber  
urgently should they be planning, or become, pregnant.
THE RISK – WHO AND WHAT
Valproate should only be used in girls, women of child bearing 
age and those who are pregnant or planning pregnancy, when 
other treatments are ineffective or not tolerated. 
Children exposed in utero to valproate  
are at a high risk of serious developmental 
disorders (in up to 30-40% of cases) and 
congenital malformations (in approximately 
10% of cases). 
To support effective practice, Valproate  
Patient Cards and Valproate Patient Guides 
are available for you to provide to female 
patients taking valproate.
These materials highlight the risks of  
taking valproate whilst pregnant and remind 
patients use effective contraception and  
to see their prescriber urgently should they 
be planning, or become, pregnant. 
CALL FOR REPORTING
 This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting 
any side effects your patients may get. See www.mhra.gov.uk/yellowcard for how to report side effects. 
June 2017  
SAGB.VPA.17.05.0570
FOR DISPENSARY USE ONLY
WARNING ON USE 
OF VALPROATE
Copies of the Valproate Patient Guide and 
Valproate Patient Cards can be ordered, at no  
cost, by contacting Sanofi Medical Information on 
0845 372 7101 or by 
emailing UK-medicalinformation@sanofi.com
The Patient Guide and Cards can also be 
downloaded from the EMC website
www.medicines.org.uk
where it will be found linked with entries for 
medicines containing valproate.
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Annex VII – Depakote US Medication guide 
  
  
 
 
 
 
  
 
 
 
 
 
 
 
  
 
MEDICATION GUIDE 

DEPAKOTE ER (dep-a-kOte) 

(divalproex sodium) 

Extended Release Tablets 

DEPAKOTE (dep-a-kOte)  

(divalproex sodium) 

Tablets 

DEPAKOTE (dep-a-kOte)  

(divalproex sodium delayed release capsules)  

Sprinkle Capsules 

DEPAKENE (dep-a-keen)  

(valproic acid)  

Capsules and Oral Solution 

Read this Medication Guide before you start taking Depakote or Depakene and each time you get 

a refill. There may be new information. This information does not take the place of talking to 
your healthcare provider about your medical condition or treatment.  
What is the most important information I should know about Depakote and Depakene?
 
Do not stop taking Depakote or Depakene without first talking to your healthcare provider.
 
Stopping Depakote or Depakene suddenly can cause serious problems.  
Depakote and Depakene can cause serious side effects, including:
1.Serious liver damage that can cause death, especially in children younger than 2 years 
old. The risk of getting this serious liver damage is more likely to happen within the first 6 
months of treatment.  
Call your healthcare provider right away if you get any of the following symptoms:
◦ nausea or vomiting that does not go away 
◦ loss of appetite 
◦ pain on the right side of your stomach (abdomen) 
◦ dark urine 
◦ swelling of your face 
◦ yellowing of your skin or the whites of your eyes 

In some cases, liver damage may continue despite stopping the drug.  

2.Depakote or Depakene may harm your unborn baby.
• If you take Depakote or Depakene during pregnancy for any medical condition, your 
baby is at risk for serious birth defects that affect the brain and spinal cord and are called 
spina bifida or neural tube defects. These defects occur in 1 to 2 out of every 100 babies 
born to mothers who use this medicine during pregnancy. These defects can begin in the 
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first month, even before you know you are pregnant. Other birth defects that affect the 
structures of the heart, head, arms, legs, and the opening where the urine comes out 
(urethra) on the bottom of the penis can also happen.  
• Birth defects may occur even in children born to women who are not taking any 

medicines and do not have other risk factors. 

• Taking folic acid supplements before getting pregnant and during early pregnancy can 
lower the chance of having a baby with a neural tube defect.  
• If you take Depakote or Depakene during pregnancy for any medical condition, your 
child is at risk for having a lower IQ. 
• There may be other medicines to treat your condition that have a lower chance of causing 
birth defects and decreased IQ in your child.  
• Women who are pregnant must not take Depakote or Depakene to prevent migraine 
headaches.
•	 All women of child-bearing age should talk to their healthcare provider about using 
other possible treatments instead of Depakote or Depakene. If the decision is made 
to use Depakote or Depakene, you should use effective birth control (contraception).
• Tell your healthcare provider right away if you become pregnant while taking Depakote 
or Depakene. You and your healthcare provider should decide if you will continue to take 
Depakote or Depakene while you are pregnant. 
Pregnancy Registry: If you become pregnant while taking Depakote or Depakene, talk 
to your healthcare provider about registering with the North American Antiepileptic Drug 
Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The 
purpose of this registry is to collect information about the safety of antiepileptic drugs 
during pregnancy. 
3. Inflammation of your pancreas that can cause death.
Call your healthcare provider right away if you have any of these symptoms:
• severe stomach pain that you may also feel in your back 
•	 nausea or vomiting that does not go away 
4.Like other antiepileptic drugs, Depakote or Depakene may cause suicidal thoughts or 
actions in a very small number of people, about 1 in 500.
Call a healthcare provider right away if you have any of these symptoms, especially if 
they are new, worse, or worry you:
◦	 thoughts about suicide or dying 
◦	 attempts to commit suicide 
◦	 new or worse depression 
◦	 new or worse anxiety 
◦	 feeling agitated or restless 
◦	 panic attacks 
◦	 trouble sleeping (insomnia) 
◦	 new or worse irritability 
◦	 acting aggressive, being angry, or violent 
◦	 acting on dangerous impulses 
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◦ an extreme increase in activity and talking (mania) 

◦ other unusual changes in behavior or mood  

How can I watch for early symptoms of suicidal thoughts and actions?
◦	 Pay attention to any changes, especially sudden changes in mood, behaviors, thoughts, or 
feelings. 
◦	 Keep all follow-up visits with your healthcare provider as scheduled. 
Call your healthcare provider between visits as needed, especially if you are worried about 
symptoms.
Do not stop Depakote or Depakene without first talking to a healthcare provider. 
Stopping Depakote or Depakene suddenly can cause serious problems. Stopping a seizure 
medicine suddenly in a patient who has epilepsy can cause seizures that do not stop (status 
epilepticus).
Suicidal thoughts or actions can be caused by things other than medicines. If you have 
suicidal thoughts or actions, your healthcare provider may check for other causes.  
What are Depakote and Depakene?
Depakote and Depakene come in different dosage forms with different usages.  
Depakote Tablets and Depakote Extended Release Tablets are prescription medicines used:  
• to treat manic episodes associated with bipolar disorder. 
• alone or with other medicines to treat: 
◦	 complex partial seizures in adults and children 10 years of age and older  
◦	 simple and complex absence seizures, with or without other seizure types 
• to prevent migraine headaches
Depakene (solution and liquid capsules) and Depakote Sprinkles are prescription medicines used 
alone or with other medicines, to treat:  
•	 complex partial seizures in adults and children 10 years of age and older 
• simple and complex absence seizures, with or without other seizure types 
Who should not take Depakote or Depakene?
Do not take Depakote or Depakene if you: 
• have liver problems
• have or think you have a genetic liver problem caused by a mitochondrial disorder (e.g. 

Alpers-Huttenlocher syndrome)
 
•	 are allergic to divalproex sodium, valproic acid, sodium valproate, or any of the ingredients 
in Depakote or Depakene. See the end of this leaflet for a complete list of ingredients in 
Depakote and Depakene. 
• have a genetic problem called urea cycle disorder 
• are pregnant for the prevention of migraine headaches 
What should I tell my healthcare provider before taking Depakote or Depakene?
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Before you take Depakote or Depakene, tell your healthcare provider if you:  
• have a genetic liver problem caused by a mitochondrial disorder (e.g. Alpers-Huttenlocher 
syndrome) 
• drink alcohol 
• are pregnant or breastfeeding. Depakote or Depakene can pass into breast milk. Talk to your 
healthcare provider about the best way to feed your baby if you take Depakote or Depakene.  
• have or have had depression, mood problems, or suicidal thoughts or behavior 
• have any other medical conditions 
Tell your healthcare provider about all the medicines you take, including prescription and 
non-prescription medicines, vitamins, herbal supplements and medicines that you take for a short 
period of time.  
Taking Depakote or Depakene with certain other medicines can cause side effects or affect how 
well they work. Do not start or stop other medicines without talking to your healthcare provider.  
Know the medicines you take. Keep a list of them and show it to your healthcare provider and 
pharmacist each time you get a new medicine.  
How should I take Depakote or Depakene?
• Take Depakote or Depakene exactly as your healthcare provider tells you. Your healthcare 
provider will tell you how much Depakote or Depakene to take and when to take it.  
• Your healthcare provider may change your dose. 
• Do not change your dose of Depakote or Depakene without talking to your healthcare 

provider. 

•	 Do not stop taking Depakote or Depakene without first talking to your healthcare
 
provider. Stopping Depakote or Depakene suddenly can cause serious problems.  

• Swallow Depakote tablets, Depakote ER tablets or Depakene capsules whole. Do not crush 
or chew Depakote tablets, Depakote ER tablets, or Depakene capsules. Tell your healthcare 
provider if you cannot swallow Depakote or Depakene whole. You may need a different 
medicine.  
• Depakote Sprinkle Capsules may be swallowed whole, or they may be opened and the 

contents may be sprinkled on a small amount of soft food, such as applesauce or pudding. 

See the Patient Instructions for Use at the end of this Medication Guide for detailed 

instructions on how to use Depakote Sprinkle Capsules.  

• If you take too much Depakote or Depakene, call your healthcare provider or local Poison 

Control Center right away. 

What should I avoid while taking Depakote or Depakene?
• Depakote and Depakene can cause drowsiness and dizziness. Do not drink alcohol or take 
other medicines that make you sleepy or dizzy while taking Depakote or Depakene, until you 
talk with your doctor. Taking Depakote or Depakene with alcohol or drugs that cause 
sleepiness or dizziness may make your sleepiness or dizziness worse.  
• Do not drive a car or operate dangerous machinery until you know how Depakote or 

Depakene affect you. Depakote and Depakene can slow your thinking and motor skills.  

What are the possible side effects of Depakote or Depakene?
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• See “What is the most important information I should know about Depakote or 

Depakene?”
 
Depakote or Depakene may cause other serious side effects including:  
•	 Bleeding problems: red or purple spots on your skin, bruising, pain and swelling into your 
joints due to bleeding or bleeding from your mouth or nose.  
•	 High ammonia levels in your blood: feeling tired, vomiting, changes in mental status.  
•	 Low body temperature (hypothermia): drop in your body temperature to less than 950F, 

feeling tired, confusion, coma.  

•	 Allergic (hypersensitivity) reactions: fever, skin rash, hives, sores in your mouth, blistering 
and peeling of your skin, swelling of your lymph nodes, swelling of your face, eyes, lips, 
tongue, or throat, trouble swallowing or breathing.  
•	 Drowsiness or sleepiness in the elderly. This extreme drowsiness may cause you to eat or 
drink less than you normally would. Tell your doctor if you are not able to eat or drink as you 
normally do. Your doctor may start you at a lower dose of Depakote or Depakene.  
Call your healthcare provider right away, if you have any of the symptoms listed above.
The common side effects of Depakote and Depakene include:
•	 nausea 
• headache 
• sleepiness
•	 vomiting
• weakness 
• tremor 
• dizziness
• stomach pain 
• blurry vision 
• double vision 
• diarrhea
• increased appetite
• weight gain 
• hair loss
• loss of appetite 
• problems with walking or coordination 
These are not all of the possible side effects of Depakote or Depakene. For more information, 
ask your healthcare provider or pharmacist.  
Tell your healthcare provider if you have any side effect that bothers you or that does not go 
away. 
Call your doctor for medical advice about side effects. You may report side effects to FDA 
at 1-800-FDA-1088.
How should I store Depakote or Depakene?
• Store Depakote Extended Release Tablets between 59°F to 86°F (15°C to 30°C). 
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• Store Depakote Delayed Release Tablets below 86°F (30°C).  
• Store Depakote Sprinkle Capsules below 77°F (25°C). 
• Store Depakene Capsules at 59°F to 77°F (15°C to 25°C). 
• Store Depakene Oral Solution below 86°F (30°C). 
Keep Depakote or Depakene and all medicines out of the reach of children.
General information about the safe and effective use of Depakote or Depakene
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. 
Do not use Depakote or Depakene for a condition for which it was not prescribed. Do not give 
Depakote or Depakene to other people, even if they have the same symptoms that you have. It 
may harm them.  
This Medication Guide summarizes the most important information about Depakote or 
Depakene. If you would like more information, talk with your healthcare provider. You can ask 
your pharmacist or healthcare provider for information about Depakote or Depakene that is 
written for health professionals. 
For more information, go to www.rxabbvie.com or call 1-800-633-9110.  
What are the ingredients in Depakote or Depakene?
Depakote:
Active ingredient: divalproex sodium
Inactive ingredients:  
•	 Depakote Extended Release Tablets: FD&C Blue No. 1, hypromellose, lactose, 
microcrystalline cellulose, polyethylene glycol, potassium sorbate, propylene glycol, silicon 
dioxide, titanium dioxide, and triacetin. The 500 mg tablets also contain iron oxide and 
polydextrose. 
•	 Depakote Tablets: cellulosic polymers, diacetylated monoglycerides, povidone, 
pregelatinized starch (contains corn starch), silica gel, talc, titanium dioxide, and vanillin.
Individual tablets also contain:
125 mg tablets: FD&C Blue No. 1 and FD&C Red No. 40, 
250 mg tablets: FD&C Yellow No. 6 and iron oxide, 
500 mg tablets: D&C Red No. 30, FD&C Blue No. 2, and iron oxide. 
• Depakote Sprinkle Capsules: cellulosic polymers, D&C Red No. 28, FD&C Blue No. 1 
gelatin, iron oxide, magnesium stearate, silica gel, titanium dioxide, and triethyl citrate.  
Depakene:
Active ingredient: valproic acid  
Inactive ingredients:  
•	 Depakene Capsules: corn oil, FD&C Yellow No. 6, gelatin, glycerin, iron oxide, 

methylparaben, propylparaben, and titanium dioxide.  

•	 Depakene Oral Solution: FD&C Red No. 40, glycerin, methylparaben, propylparaben, 

sorbitol, sucrose, water, and natural and artificial flavors.  
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Depakote ER:
250 mg is Mfd. by AbbVie LTD, Barceloneta, PR 00617  
500 mg is Mfd. by AbbVie Inc., North Chicago, IL 60064 U.S.A. or 
AbbVie LTD, Barceloneta, PR 00617 
For AbbVie Inc., North Chicago, IL 60064 U.S.A. 
Depakote Tablets:
Mfd. by AbbVie LTD, Barceloneta, PR 00617 

For AbbVie Inc., North Chicago, IL 60064, U.S.A. 

Depakote Sprinkle Capsules:
AbbVie Inc., North Chicago, IL 60064, U.S.A. 
Depakene Capsules:
Mfd. by Banner Pharmacaps, Inc., High Point, NC 27265 U.S.A. 

For AbbVie Inc., North Chicago, IL 60064, U.S.A. 

Depakene Oral solution:
Mfd. by AbbVie Inc., North Chicago, IL 60064, U.S.A. 

OR by DPT Laboratories, Ltd., San Antonio, TX 78215, U.S.A. 

For AbbVie Inc., North Chicago, IL 60064, U.S.A. 

This Medication Guide has been approved by the U.S. Food and Drug Administration.  
©2017 AbbVie Inc. 
Revised: March 2017 
03-B501 
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Annex VIII - Supplementary Data File 
 
The accompanying Excel spreadsheet shows the raw data collated and used for the 
analysis of safety-related regulatory actions in the EU and US territories with regards to 
direct communication with Health Care Providers and withdrawals. 
Filename: Raw_data_Ana_Tiago 
